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ABSTRACT
LIDDY MIAOLI CHEN: DESIGN CONSIDERATIONS FOR COMPLEX
SURVIVAL MODELS.
(Under the direction of Dr. Joseph G. Ibrahim and Dr. Haitao Chu.)
Various complex survival models, such as joint models of survival and longitudinal
data and multivariate frailty models, have gained popularity in recent years because
these models can maximize the utilization of information collected. It has been shown
that these methods can reduce bias and/or improve eﬃciency, and thus can increase
the power for statistical inference. Statistical design, such as sample size and power
calculations, is a crucial ﬁrst step in clinical trials.
We derived a closed form sample size formula for estimating the eﬀect of the longitu-
dinal process in joint modeling, and extend Schoenfeld’s (1983) sample size formula to
the joint modeling setting for estimating the overall treatment eﬀect. The sample size
formula we developed is general, allowing for p-degree polynomial trajectories. The ro-
bustness of our model was demonstrated in simulation studies with linear and quadratic
trajectories. We discussed the impact of the within subject variability on power, and
data collection strategies, such as spacing and frequency of repeated measurements, in
order to maximize power. When the within subject variability is large, diﬀerent data
collection strategies can inﬂuence the power of the study in a signiﬁcant way.
We also developed a sample size determination method for the shared frailty model
to investigate the treatment eﬀect on multivariate time to events, including recurrent
events. We ﬁrst assumed a common treatment eﬀect on multiple event times, and the
sample size determination was based on testing the common treatment eﬀect. We then
considered testing the treatment eﬀect on one time-to-event while treating the other
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time-to-events as nuisance, and compared the power from a multivariate frailty model
versus that from a univariate parametric and semi-parametric survival model. The
multivariate frailty model has signiﬁcant advantage over the univariate survival model
when the time-to-event data is highly correlated.
Group sequential methods had been developed to control the overall type I error rate
in interim analysis of accumulating data in a clinical trial. These methods mainly apply
to testing the same hypothesis at diﬀerent interim analyses. Finally, we extended the
methodology of the alpha spending function to group sequential stopping boundaries
when the hypotheses can be diﬀerent between analyses. We found that these stopping
boundaries depend on the Fisher’s Information matrix, and application to a bivariate
frailty model and a joint model was considered.
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CHAPTER 1
Introduction and Literature Review
1.1 Introduction
Various complex survival models, such as joint models of survival and longitudinal data
and multivariate frailty models, have gained popularity in recent years because these
models can maximize the utilization of information collected. Classical models such as
the Cox proportional hazard model to handle time-to-event data and the mix model
to handle repeated measurements evaluate the treatment eﬀect on these two types of
responses separately. There are two complications in describing or making inference
on the longitudinal process in these studies: 1) Occurrence of the time-to-event may
induce an informative censoring (Wu and Carroll 1988, Hogan and Laird 1997ab), as
subjects who have early events would be censored at an earlier time point. 2) The
longitudinal data is only available intermittently for each subject, and likely subjects
to measurement errors. These concerns led to the development of joint models of the
two data types. Joint models are also developed because there is a need to take into
account the dependency of these two data types when investigating the treatment eﬀect
on survival.
The need to study or analyze multiple correlated time-to-event data arises in many
experimental design and observational studies. The frailty model has been becoming
increasingly popular for analyzing multivariate time-to-event data (Oakes 1989, Peter-
son 1998, Duchateau et al. 2003, Cook and Lawless 2007, Zeng et al. 2009) because it
provides a convenient way to introduce association and unobserved heterogeneity into
models for the multivariate survival data. A frailty, a concept introduced by Vaupel et
al. (1979), is an unobservable random eﬀect. A natural way to model dependence of
clustered or multivariate event times is through the introduction of a cluster-speciﬁc
random eﬀect. This random eﬀect explains the dependence in the sense that had we
known the frailty, the events would be independent.
Design is a crucial ﬁrst step in clinical trials. Well-designed studies are essential
for successful research and drug development. Although much eﬀort has been put into
inferential and estimation methods in these complex survival models, design researches
are lacking. Sample size determination for these models have not been formally consid-
ered. There has been little guidance in the methodologic literature as to how researchers
should select the number of repeated measures for the longitudinal data. Hence devel-
oping statistical methods to address design issues in joint modeling and multivariate
frailty model are much needed.
Interim analyses are also commonly used in clinical trials due to diﬃculty in enroll-
ment, and/or long follow-up time until enough events have occurred. Although much
ﬂexibility has been achieved with the alpha spending function in group sequential de-
signs, the unique feature of joint model also brings up another group sequential design
model. In Chapter 2, a sample size formula to study the association between the time-
to-event and the longitudinal data is provided, followed by detailed discussion of the
methodology when the variance-covariance matrix is known or unknown. Longitudinal
data collection strategies, such as spacing and frequency of repeated measurements, to
maximize the power are also discussed. Chapter 3 provides a sample size determination
formula to study a common treatment eﬀect for the multivariate time-to-event data,
and a sample size formula to investigate the treatment eﬀect on a single event time
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while taking into account the dependency of clustered event times. Group sequential
design when diﬀerent parameters are involved is discussed is discussed in Chapter 4,
followed by application in multivariate survival models and joint models.
1.2 Joint Models in the Literature
1.2.1 Two-Step Models
The earliest literature on joint modeling focuses on a two-step inferential strategy which
deﬁnes sub-models for the longitudinal and event time processes (Self and Pawitan 1992,
Tsiatis and Wulfsohn 1995). In “ideal” data situation, the longitudinal process follows
a well-deﬁned trajectory, {Xi(u), u ≥ 0)}, for all times u ≥ 0 for each subject i =
1, . . . , n. A routine framework to study the association between the time-to-event and
the treatment eﬀect, or the association between the time-to-event and the longitudinal
data, is to represent the relationship between the event time (Ti), the trajectory (Xi(u)),
and the baseline covariates (Zi) by a proportional hazard model (Cox 1975)
λi(u) = lim
du→0
du−1pr
{
u ≤ ti < u + du|ti ≥ u,XHi (u),Zi
}
= λ0(u)exp
{
βXi(u) + α
TZi
}
, (1.1)
where XHi (u) = {Xi(t), 0 ≤ t < u} is the history of the longitudinal process up to time
u. Inference on β and α can be made by maximizing the partial likelihood.
n∏
i=1
[
exp{βXi(Si) + αTZi}∑n
k=1 exp{βXk(Si) + αTZk}I(Sk ≥ Si)
]Δi
, (1.2)
where Si = min(Ti, Ci) (Ti and Ci denote the event and censoring times, respectively)
and Δi = I(Ti ≤ Ci). However, Xi(u) is unknown, and the response is collected on
each subject only intermittently at time tij ≤ Si, j = 1, . . . ,mi. For such a model, the
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value of
f
(
X(u), β, α
)
= exp{βX(u) + αTZ}
is given by
E
[
exp{βX(u) + αTZ|Y¯ (u), u < S}], (1.3)
where Y¯ (u) is the history of observed longitudinal data up to time u. Theoretical
justiﬁcation for this two-stage model is that the value of (1.3) can be approximated by
a ﬁrst-order approximation:
E
[
exp{βX(u) + αTZ|Y¯ (u), u < S}]
≈ exp{βE[X(u)|Y¯ (u), u < S]+ αTZ}.
Therefore, we can replace the unknown value, Xi(Si) in (1.2) with E
[
Xi(Si)|Y¯i(Si)
]
.
Let Yi(tij) = Xi(tij) + ei(tij) denote the observed value of Xi(tij), where ei(tij) is an
intra-subject error and is normally distributed with mean 0. Tsiatis and Wulfsohn
(1995) proposed a simple linear model
Xi(u) = θ0i + θ1iu (1.4)
to represent the log CD4 trajectories. A more general polynomial model Xi(u) = θ0i +
θ1iu+θ2iu
2+ · · ·+θpiup had been considered in later studies (Chen et al. 2004, Ibrahim
et al. 2004). In this model, it is assumed that each subject followed his or her own
trajectory with intercept θ0i and slope θ1i. (θ0i, θ1i)
T are i.i.d bivariate normal vectors
with mean (μ0, μ1)
T and variance-covariance Σθ. Consequently, E
[
Xi(Si)|Y¯i(Si)
]
can
be represented by θˆ0i and θˆ1i, the Bayes estimates of θ0i and θ1i. One way to obtain
these estimates is by using the linear random components model as described by Laird
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and Ware (1982).
1.2.2 The Likelihood Approach
Several drawbacks to the two-step modeling were discussed by Wulfsohn and Tsiatis
(1997), and Tsiatis and Davidian (2004). The most important drawback is that the
random eﬀects in those at risk at each event time is probably not normally distributed,
a critical assumption for the mixed model. If the longitudinal data is predictive of
survival, patients with the steepest slope will be removed from the at risk population
at an earlier time point. Thus it is less likely that the normality assumption still holds as
time progresses. Other drawbacks include the validity of the ﬁrst order approximation
and less eﬃcient use of information.
Wulfshon and Tsiatis (1997) proposed a full data likelihood incorporating a linear
model for the longitudinal data and the Cox model for the time-to-event data as
∫ ∞
−∞
[
mj∏
j=1
f(Yij|θi, σ2e)
]
f(θi|μθ,Σθ)f(Si,Δi|θi, β)dθi. (1.5)
In expression (1.5), f(Yij|θi, σ2e) is a univariate normal density function with mean
θ0i + θ1itij and variance σ
2
e , and f(θi|μθ,Σθ) is the multivariate normal density with
mean μθ and covariance matrix Σθ. The density function for the time-to-event is based
on Cox partial likelihood, where
f(Si,Δi|θi, β, α) = {λ0(Si) exp[β(θ0i + θ1iSi)]}Δi
× exp
[
−
∫ Si
0
λ0(t) exp[β(θ0i + θ1it]dt
]
.
The parameters θ, Σθ, σ
2
e , and β were estimated using parametric maximum likelihood,
and λ0(t) was estimated using nonparametric maximum likelihood. An EM algorithm
was developed to obtain these estimates. They obtained parameter estimates that were
5
similar to those from the two-step model (the same data was used), with βˆ further from
the null as compared to that from the two-step model.
Alternative forms to model the “true” longitudinal process has been considered
(Song et al. 2002b, Taylor et al. 1994, Lavalley & DeGruttola 1996, Wang & Taylor
2001, Henderson et al. 2000, and Xu & Zeger 2001)
1.3 Multivariate Frailty Models in the Literature
The shared frailty model, ﬁrst introduced by Clayton (1978), assumes that individuals
in a cluster or repeated measurements of an individual share the same frailty, ω, and the
survival times are assumed to be conditional independent with respect to the shared
(common) frailty. Conditional on the frailty, the hazard function of an event in an
individual, or an individual in a cluster is of the form ωλ0(t)exp(β
TX), where ω is
common to all events in an individual. The survival function is given as
S(t1, . . . , tK |ω) = S1(t1)ωS2(t2)ω . . . SK(tK)ω.
Independence of the survival times within an individual corresponds to a degenerate
frailty distribution with variance equals 0. One major consideration in the frailty mod-
els is the choice of the frailty distribution. Clayton (1978) and Oakes (1982) ﬁrst
considered frailty models with gamma distribution for the frailty. In a gamma frailty
model, the frailty can be easily integrated out and thus the data likelihood has a closed
form. This is also the model considered in this paper. Hougaard discussed multivari-
ate failure models, where the frailty follows a positive stable distribution (Hougaard
1986a) or a power variance family (PVF) distribution (Hougaard 1986b). Whitmore
and Lee (1991) proposed a model with inverse Gaussian frailty and constant hazard.
The compound Poisson frailty model was considered by Aalen (Aalen 1988, 1992). The
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Lognormal frailty model (McGilchrist and Aisbett 1991, Korsgaard et al. 1998) has
gained popularity recently especially in Bayesian models. The selection of the family
of frailty distributions, based on the properties of the various models was discussed by
Hougaard (1995).
Besides the shared frailty model, other frailty models have been considered to handle
more complex multivariate time-to-event data. The correlated frailty model (Pickles
et al. 1994, Yashin & Iachine 1995, Wienke et al. 2001) is not constrained to have a
common frailty. The frailty for each event time is associated by a joint distribution
instead. Price and Manatunga (2001) considered the use of cure frailty models to
analyze a leukaemia recurrence with a cured fraction. The nested frailty model that
accounts for the hierarchical clustering of the data by including two nested random
eﬀects is considered by Rondeau et al. (2006). Most recently, joint frailty models for
modeling recurring events and death has been proposed (Rondeau et al. 2007).
1.4 Group Sequential Methods and Alpha Spend-
ing Functions in the Literature
It is fundamental to have a trial that is properly designed to answer the scientiﬁc
question, such as whether the drug improves overall survival, and every trial design
is striving to answer the question with most robustness and accuracy while involving
the least number of patients and the shortest duration of time. Theories for group
sequential clinical trials has developed largely during the past few decades so that
a trial can be stopped early if there is strong evidence of eﬃcacy during any planned
interim analysis. A high degree of ﬂexibility has been established with respect to timing
of the analyses and how much type I error (alpha) to spend at each analyses. Popular
methods include the Pocock group sequential boundaries (Pocock 1977), the O’Brien-
Fleming boundaries (O’Brien and Fleming 1979), and the alpha spending functions
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ﬁrst introduced by Lan and DeMets (1983).
1.4.1 Group Sequential Boundaries
Let Z(k) denote the test statistic using the cumulative data up to analysis k, and Z∗(k)
denote the test statistic using data accumulated between the (k−1)th analysis the kth
analysis, then
Z(k) = {Z∗(1) + · · ·+ Z∗(k)}/
√
k.
The distribution of Z(k)
√
k can be written as a recursive density function evalu-
able by numerical integration (Armitage et al. 1969). The probability of crossing the
boundary for the very ﬁrst time at each interim analysis can be calculated based on
this density function. Under H0, the sum of these probabilities should equal to the
nominal overall type I error rate for the group sequential design.
Pocock (1977) ﬁrst proposed that the crossing boundary be constant for all equally
spaced analyses, with zc(k) = zc for all k = 1, 2 . . . , K. O’Brien and Fleming (1979)
suggested that zc(k) be changed over the K analyses such that zc(k) = zOBF
√
K/k. In
both procedures, the number of interim analyses and the timing of the interim analyses
need to be pre-determined. The O’Brien-Fleming boundaries have been used more
frequently because it still preserves a nominal signiﬁcance level at the ﬁnal analysis
that is close to that of a single test procedure. An earlier work by Haybittle and
Peto (Haybittle 1971, Peto et al. 1976) in a less formal structure suggested to use
an arbitrarily large value for the crossing boundary for each interim analysis, and the
boundary for the ﬁnal analysis should be determined such that the overall type I error
rate be preserved.
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1.4.2 The Alpha Spending Function
The alpha spending function initially developed by Lan and DeMets (1983) over the
course of a group sequential clinical trial is a more ﬂexible group sequential procedure
that does not require the total number nor the exact time of the interim analyses to be
speciﬁed in advance.
Speciﬁcally, let T denote the scheduled end of the trial, and t∗ denote the fraction
of information that has been observed at calendar time t (t ∈ [0, T ]. Also let ik, k =
1, 2, . . . , K denote the information available at the kth interim analysis at calendar time
tk, so t
∗
k = ik/I, where I is the total information. Lan and DeMets speciﬁed an alpha
spending function such that α(0) = 0 and α(1) = α. Boundary values zc(k) can be
determined successively so that
P0{|Z(1)| ≥ zc(1), or|Z(2)| ≥ zc(2), or . . . , or|Z(k)| ≥ zc(k)} = α(t∗k) (1.6)
where {Z(1), . . . , Z(k)} are the test statistics from the interim analyses 1, . . . , k.
Alpha spending functions that approximate O’Brien-Fleming or Pocock Boundaries
are as follows:
O’Brien-Fleming: α1(t
∗) = 2− 2Φ(Zα/2/
√
t∗)
Pocock: α2(t
∗) = αIn(1 + (e− 1)t∗)
where Φ denotes the standard normal cumulative distribution function. The other
alpha spending function proposed in the paper is α3(t
∗) = αt∗, representing uniform
spending of alpha over time. α3(t
∗) is intermediate between functions α1(t∗) and α2(t∗).
To solve for the boundary values zc(k), we need to obtain the multivariate distribution
of Z(1), Z(2), . . . , Z(k). In most cases, the distribution is asymptotically multivariate
normal, and the covariance structure is simple when the test statistics involve the same
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parameter at each interim analysis.
σlk = cov{Z(l), Z(k)}
=
√
t∗l /t
∗
k =
√
il/ik
=
√
nl/nk, l ≤ k,
where nl and nk are the number of subjects included in the lth and kth interim analy-
ses. If the information increments have independent distributional structure, which is
usually the case, derivation of zc(k) based on α(t
∗) is relatively straightforward with
this covariance structure using the methods of Armitage et al. (1969).
Earlier development of the alpha spending function was based on assumption that
information accumulated between each interim analysis is independent. However, the
assumption does not apply to longitudinal studies for sequential test of slopes in which
the total information is unknown. Sequential analysis using the linear random-eﬀects
model suggested by Laird and Ware (1982) has been considered by Lee and DeMets
(1991), and Wu and Lan (1992). The sequence of test statistics still has a multivari-
ate normal distribution but with a complex covariance. There have been debates on
whether the alpha spending function can still be used since the independent increment
structure doesn’t hold and the information fraction is unknown (Wei et al. 1990, Su
and Lachin 1992). It was argued by DeMets and Lan (1994) that the alpha spending
function can still be used with a more complex correlation between the successive test
statistics. The key to using the alpha spending function is being able to deﬁne the
information fraction. Although the correlation between successive test statistics will
not be exactly known, it can be estimated by a “surrogate” of the information fraction.
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CHAPTER 2
Sample Size and Power
Determination in Joint Modeling of
Longitudinal and Survival Data
2.1 Introduction
Censored time-to-event data, such as time to failure or time to death, is a common
primary endpoint in many clinical trials. Many studies also collect longitudinal data
with repeated measurements at a number of time points prior to the event, along with
other baseline covariates. The most original example is an HIV trial that compares
time to virologic failure or time to progression to AIDS (Tsiatis et al. 1995, Wulfsohn
& Tsiatis 1997). CD4 cell counts were considered a strong indicator of treatment eﬀect
and are usually measured at each visit as secondary eﬃcacy endpoints. Although CD4
cell counts are no longer considered a valid surrogate for time to progression to AIDS in
the current literature, the joint modeling strategies originally developed for these trials
led to research on joint modeling in other research areas. As discoveries of biomarkers
advance, there are more and more oncology studies that collect repeated measurements
of biomarker data, such as the prostate speciﬁc antigen (PSA) in prostate cancer trials,
as secondary eﬃcacy measurements (Renard et al. 2003). Many studies also measure
quality of life (QOL) or depression measures together with survival data where joint
models can also be applied (Ibrahim et al. 2001, Billingham & Abrams 2002, Bowman
& Manatunga 2005, Zeng & Cai 2005, Chi & Ibrahim 2006, Chi & Ibrahim 2007).
Most clinical trials are designed to address the treatment eﬀect on a time-to-event
endpoint. Recently, there has been an increasing interest in focusing on two primary
endpoints such as time-to-event and a longitudinal marker, and also to characterize the
relationship between them. For example, if treatment has an eﬀect on the longitudinal
marker and the longitudinal marker has a strong association with the time-to-event,
the longitudinal marker can potentially be used as a surrogate endpoint or a marker
for the time-to-event, which is usually lengthy to ascertain in practice. The issue of
surrogacy of a disease marker for the survival endpoint by joint modeling was discussed
by Taylor and Wang (2002).
Characterizing the association between time-to-event and the longitudinal process
is usually complicated due to incomplete or mis-measured longitudinal data (Tsiatis et
al. 1995, Wulfsohn & Tsiatis 1997, Tsiatis & Davidian 2004). Another issue is that
occurrence of the time-to-event may induce informative censoring of the longitudinal
process (Hogan & Laird 1997b, Tsiatis & Davidian 2004). The recently developed
joint modeling approaches are frameworks which acknowledge the intrinsic relationships
between the event and the longitudinal process by incorporating a trajectory for the
longitudinal process into the hazard function of the event, or in a more general sense,
introducing shared random eﬀects in both the longitudinal model and the survival
model (Wulfsohn & Tsiatis 1997, Henderson et al. 2000, Wang & Taylor 2001, Lin
et al. 2002, Song et al. 2002b, Zeng & Cai 2005). Bayesian approaches that address
joint modeling of longitudinal and survival data were introduced by Ibrahim et al.
(2001), Chen et al. (2004), Brown and Ibrahim (2003), Ibrahim et al. (2004), and Chi
and Ibrahim (2006, 2007). It has been demonstrated through simulation studies that
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use of joint modeling leads to correction of biases and improvement of eﬃciency when
estimating the association between the event time and the longitudinal process (Hsieh
et al. 2006). A thorough review on joint modeling is given by Tsiatis and Davidian
(2004). Further generalizations to multiple time-dependent covariates was introduced
by Song et al. (2002a), and a full likelihood for joint modeling of a bivariate growth
curve from two longitudinal measures and event time was introduced by Dang et al.
(2007).
Design is a crucial ﬁrst step in clinical trials. Well-designed studies are essential
for successful research and drug development. Although much eﬀort has been put into
inferential and estimation methods in joint modeling of survival and longitudinal data,
design issues have not been formally considered. Hence developing statistical methods
to address design issues in joint modeling are much needed. One of the fundamental
issues is power and sample size calculations for joint models. In this paper, we will ﬁrst
provide a sample size formula for study design based on joint modeling (Section 2.3).
In Section 2.4, we provide a detailed methodology to determine the sample size and
power with an unknown variance-covariance matrix, discuss longitudinal data collec-
tion strategies, such as spacing and frequency of repeated measurements, to maximize
the power. In Sections 2.5 and 2.6, we provide a sample size formula to investigate
treatment eﬀects in joint models, and discuss how ignoring the longitudinal process
would lead to biased estimates of the treatment eﬀect and a potential loss of power. In
Section 2.7, we provide a brief comparison between a two-step inferential approach and
the full joint modeling approach, and show that the sample size formulas we develop
are quite robust.
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2.2 Preliminaries
For subject i, (i = 1, . . . , N), let Ti and Ci denote the event and censoring times,
respectively; Si = min(Ti, Ci) and Δi = I(Ti ≤ Ci). Let Zi be a treatment indicator,
and let Xi(u) be the longitudinal process (also referred to as the trajectory) at time
u ≥ 0. In a more general sense, Zi can be a q-dimensional vector of baseline covariates
including treatment. To simplify the notation, Zi denotes the treatment indicator in
this paper. Values of Xi(u) are measured intermittently at times u ≤ Si, j = 1, . . . ,mi,
for subject i. Let Y (tij) denote the observed value of Xi(tij) at time tij, which may be
prone to measurement error.
The joint modeling approach links two sub-models, one for the longitudinal process
Xi(u) and one for the event time Ti, by including the trajectory in the hazard function
of Ti. Thus,
λi(t) = λ0(t) exp{βXi(t) + αZi}. (2.1)
Although other models for Xi(u) have been proposed (Henderson et al. 2000; Wang
and Taylor 2001, Zeng and Cai 2005), we focus on a general polynomial model (Chen
et al. 2002, Ibrahim et al. 2004),
Xi(u) = θ0i + θ1iu + θ2iu
2 + · · ·+ θpiup + γZi, (2.2)
where θi = {θ0i, θ1i, . . . , θpi}T is distributed as a multivariate normal distribution with
mean μθ and variance-covariance matrix Σθ. The parameter γ is a ﬁxed treatment
eﬀect. The observed longitudinal measures are modeled as Yi(tij) = Xi(tij)+eij, where
eij ∼ N(0, σ2e), the θi′s are independent and Cov(eij, eij′) = 0, for j 	= j′. The observed
data likelihood for subject i is given by:
∫ ∞
−∞
[
mj∏
j=1
f(Yij|θi, γ, σ2e)
]
f(θi|μθ,Σθ)f(Si,Δi|θi, β, γ, α)dθi (2.3)
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In expression (2.3), f(Yij|θi, γ, σ2e) is a univariate normal density function with
mean θ0i + θ1itij + θ2it
2
ij + · · · + θpitpij + γZi and variance σ2e , and f(θi|μθ,Σθ) is
the multivariate normal density with mean μθ and covariance matrix Σθ. The den-
sity function for the time-to-event, f(Si,Δi|θi, β, γ, α), can be based on any model.
In this paper, we focus on the exponential model, where f(Si,Δi|θi, β, γ, α) =
{λ0 exp[βX(Si) + αZi]}Δi exp
[
− ∫ Si
0
λ0 exp[βX(t) + αZi]dt
]
.
2.3 Sample Size Determination for Studying the
Relationship between Event Time and the Lon-
gitudinal Process
The sample size formula presented in this section is based on the assumption that the
hazard function follows model (2.1) in Section 2.2 and the trajectory follows a general
polynomial model as speciﬁed in (2.2) of Section 2.2. No time-by-treatment interaction
is assumed with the longitudinal process. The primary objective is to test the eﬀect of
the longitudinal process (H0: β = 0) by the score statistic, based on a two-step model
(when Σθ is unknown) or the partial likelihood (when Σθ is known).
2.3.1 Known Σθ
We start by assuming a known trajectory, Xi(t), so that the score statistic can be
derived directly based on the partial likelihood. We show in the Section 2.9, Appendix
A that the score statistic converges to a function of Var{Xi(t)}, and thus a function of
Σθ. When Σθ is known, and assuming that the trajectory follows a general polynomial
function of time as in (2.2), we derive a formula for the number of events required
for a one-sided level α˜ test with power β˜ (see detailed derivation in the Section 2.9),
Appendix A. This formula is given by
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D =
(zβ˜ + z1−α˜)
2
σ2sβ
2
, (2.4)
where
σ2s = Var(θ0k) +
p∑
j=1
Var(θjk)E{I(T ≤ t¯f )T 2j}/τ
+ 2
p∑
j=0
p∑
l>j
Cov(θjk, θlk)E{I(T ≤ t¯f )T j+l}/τ, (2.5)
p is the degree of polynomial in the trajectory, τ = D
N
is the event rate, and t¯f is
the mean follow-up time for all subjects. E{(I ≤ t¯f )T q} is a truncated moment of
T q. It can be estimated by assuming a particular distribution of T, the event time,
and a mean follow-up time. Therefore, the power for estimating β depends on: (a)
The expected log-hazard ratio associated with a unit change in the trajectory, or the
size of β. As β increases, the required sample size decreases; (b) Σθ ( Var(θji) and
Cov(θji, θli) ). A larger variance and positive covariances lead to smaller sample sizes,
while larger negative covariances imply less heterogeneity and require larger sample
sizes; and (c) The truncated moments of the event time, T , which depends on both the
median survival and length of follow-up. Larger E{(I ≤ t¯f )T q} implies larger σ2s , and
thus requires smaller sample size. Details for estimating E{(I ≤ t¯f )T q} are provided in
Section 2.3.3. Since τ , the event rate, also aﬀects σ2s , censored observations do in fact
contribute to the power when estimating the trajectory eﬀect.
Speciﬁc assumptions regarding Σθ are required in order to estimate σ
2
s , regardless
of whether Σθ is assumed known or unknown (see Sections 2.3.2 and 2.4). It is usually
diﬃcult to ﬁnd relevant information concerning each variance and covariance for the
θ’s, especially when the dimension of Σθ, or the degree of polynomial in the trajectory
is high. A structured covariance matrix, such as an autoregressive or compound sym-
metry, can be used. One can simplify formula (2.5) with a structured covariance. This
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also facilitates the selection of a covariance structure in the ﬁnal analysis.
2.3.2 Unknown Σθ
Tsiatis et al. (1995) developed a two-step inferential approach based on a ﬁrst-order
approximation, E[f(X(t), β|Y¯ (t), S ≥ t)] ≈ f [E(X(t)|Y¯ , S ≥ t, β)]. As noted above,
X(t) is the unobserved true value of the longitudinal data at time t, and Y¯ (t) de-
notes the observed history up to time t. Under this approximation, we can replace
{θ0i, θ1i, . . . , θpi}T in the Cox model with the empirical estimates {θˆ0i, θˆ1i, . . . , θˆpi}T de-
scribed by Laird and Ware (1982). The Cox partial likelihood (Cox 1975) can then be
used for inferences in obtaining parameter estimates without using the full joint like-
lihood. Despite several drawbacks to this two-stage modeling approach (Wulfsohn &
Tsiatis 1997), it has two major advantages: (a) the likelihood is simpler and standard
statistical software for the Cox model can be used directly for inferences and estima-
tion; (b) it can correct bias caused by missing data or mis-measured time-dependent
covariates. Therefore, when Σθ is unknown, the trajectory is characterized by the em-
pirical Bayes estimates of θˆi. Σθ in equation (2.5) can then be replaced with an overall
estimate of Σθˆi , where Σθˆi is the covariance matrix of {θˆ0i, θˆ1i, . . . , θˆpi}T .
Σθˆi is clearly associated with the frequency and spacing of repeated measurements
on the subjects, duration of the follow-up period, and the within subject variability,
σ2e (Fitzmaurice et al. 2004). Since Σθ is never known in practice, sample size de-
termination using Σθ in equation (2.5) will likely over-estimate the power. Therefore,
we need to understand how the longitudinal data (i.e., the frequency of measurements,
the spacing of measurements etc.) aﬀects Σθˆi , and design a data collection strategy to
maximize the power for the study. We defer the discussion of this issue to Section 2.4.
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2.3.3 Truncated Moments of T
To obtain the truncated moments of T q, E{(I ≤ t¯f )T q}, in equation (2.5), we must
assume a distribution for T . In practice, the exact distribution for T is unknown.
However, the median event time or event rate at a ﬁxed time point for the study
population can usually be obtained from the literature. It is a common practice to
assume that T follows an exponential distribution with exponential parameter η in the
study design stage. Thus, the truncated moment of T q only depends on η and t¯f , and
has the following form:
E{I(T ≤ t¯f )T q} =
∫ t¯f
0
T qη exp(−ηT )dT = 1
ηq
Γ(q + 1, t¯f ),
where Γ(q+1, t¯f ) is a lower incomplete gamma function with q = {1, 2, 3, . . . . . . }. η can
be estimated based on the median event time or event rate at a ﬁxed time point. E.g.,
if the median event time, TM , is known for the study population, η = − log(0.5)/TM .
When the trajectory is a linear function of time,
σ2s = var(θˆ0i) +
1
τ
E[I(T ≤ t¯f )T 2]var(θˆ1i)
+
2
τ
E[I(T ≤ t¯f )T ]cov(θˆ0i, θˆ1i) .
Both E{I(T ≤ t¯f )T 2} and E{I(T ≤ t¯f )T} have closed-form expressions, given by:
E{I(T ≤ t¯f )T 2} =
∫ t¯f
0
T 2η exp(−ηT )dT
=
2
η2
− exp(−ηt¯f )(t¯2f +
2t¯f
η
+
2
η2
),
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and
E{I(T ≤ t¯f )T} =
∫ t¯f
0
Tη exp(−ηT )dT
=
1
η
− exp(−ηt¯f )(t¯f + 1
η
).
There are certain limitations of this distributional assumption for T . It does not take
into account covariates that are usually considered in the exponential or Cox model for
S. A more complex distributional assumption can be used to estimate E{(I ≤ t¯f )T q}
if more information is available. However, simple distributional assumptions for T ,
without the inclusion of covariates or using an average eﬀect of all covariates, is easy
to implement and it is usually adequate for sample size or power determination.
E{(I ≤ t¯f )T q} also depends on t¯f , the mean follow-up time for all subjects. It
is truncated because we typically cannot observe all events in a study. Therefore,
it is heavily driven by the censoring mechanism, and can be approximated by the
mean follow-up time in censored subjects. One way to estimate t¯f is take the average
of the minimum and maximum follow-up times if censoring is uniform between the
minimum and maximum follow-up times. It can also be estimated based on more
complex methods. If data from a similar study is available, t¯f can be estimated with
the product-limit method by switching the censoring indicator so that censored cases
would be considered as events and events would be considered as censored.
2.3.4 Simulation Results
We ﬁrst veriﬁed in simulation studies that when Σθ is known, formula (2.4) provides
an accurate estimate of the power for estimating β. Table 2.1 shows a comparison
of the calculated power based on equations (2.4) and (2.5), and empirical power in a
linear trajectory with known Σθ. In this simulation study, the event time was simulated
from an exponential model with λi(t) = λ0(t) exp{βXi(t) + αZi}, where Xi(t) = θ0i +
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TABLE 2.1: Validation of formula (2.4) for testing the trajectory eﬀect β when Σθ
is known
Power for Estimating β a
β V ar(θ0i) V ar(θ1i) Cov(θ0i, θ1i) Empirical Calculated
0.15 0.5 0.9 0 41.6 39.8
0.15 0.8 1 0 52.9 52.4
0.15 0.8 1 0.5 66.1 67.0
0.2 1.2 0.7 0 87.1 86.0
0.2 0.7 1.2 0 75.9 76.4
0.2 0.7 1.2 0.2 82.7 82.7
0.2 0.7 1.2 -0.2 69.8 68.4
aCovariance matrix of (θ0i, θ1i) is assumed known. Empirical power is based on 1000 simulations,
each with 100 subjects per arm. Minimum follow-up time is 0.75 years (9 months), and maximum
follow-up time is 2 years. Event time is simulated from an exponential distribution with λ0 = 0.85,
α = 0.3, and γ = 0.1. The θ’s are simulated from a normal distribution with E(θ0i) = 0, E(θ1i) = 3.,
and Σθ as speciﬁed in columns 2-4.
θ1it + γZi. To ensure a minimum follow-up time of 0.75 years (9 months), censoring
was generated from a uniform [0.75, 2] distribution. (θ0i θ1i) was assumed to follow a
bivariate normal distribution. We simulated 1000 trials and each trial has 200 subjects.
Empirical power was the % of trials with a p-value from the score test ≤ 0.05 for testing
H0: β = 0. The quantities D, η, and t¯f were obtained based on the simulated data,
η was obtained from the median survival of the simulated data, and t¯f was the mean
follow-up time of the simulated data using the product limit method. Thus Table
2.1 shows that if the input parameters are correct, formula (2.4) returns an accurate
estimate of power in various Σθ.
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2.4 Estimating Σθˆi and Maximization of Power
Following the notation in Section 2.2, LetRi =
⎛
⎜⎜⎜⎜⎜⎜⎜⎝
1 ti1 . . . ti1
p
1 ti2 . . . ti2
p
...
...
. . .
...
1 timi . . . timi
p
⎞
⎟⎟⎟⎟⎟⎟⎟⎠
be a mi×(1+p)
matrix, and Zi = 1miZi, V ar(Yi) = Vi = Imiσ
2
e +RiΣθRi
T and Wi = Vi
−1, then θˆi
and Σθˆi can be expressed as (Laird & Ware 1982)
θˆi − μθ = ΣθRiTWi(Yi − γˆZi),
and
Var(θˆi) = Σθˆi =
ΣθRi
T
⎧⎨
⎩Wi −WiZi
(
N∑
i
Zi
TWiZi
)−1
Zi
TWi
⎫⎬
⎭RiΣθ. (2.6)
Based on equation (2.6), Σθˆi is associated with the following: (a) The degree of the
polynomial in (2.2); (b) Σθ, that is, the between subject variability; (c) σ
2
e , the within
subject variability; (d) tij, time of the repeated measurements of the longitudinal data.
Larger tij implies a longer follow-up period, or more data collection points towards the
end of the trial, and (e) mi, the frequency of the repeated measurements. (a)-(c) above
are likely determined by the intrinsic nature of the longitudinal data, and have little
to do with the data collection strategy during the trial design. Based on (2.6), Σθˆi is
associated with the inverse of σ2e , meaning larger σ
2
e will lead to smaller Σθˆi , and thus a
decrease in power for estimating β. This is conﬁrmed in the simulation studies (Table
2.2).
Although σ2e , the within subject variability, can be reduced by using a more reliable
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measurement instrument, this is not always possible. We therefore focus on investi-
gating the impact of (d) and (e). Note that the hazard function can be written as
λi(t) = λ0(t) exp {β(θ0i + θ1it + · · ·+ θpitp) + β∗Zi}, where β∗ = βγ + α. In the design
stage, instead of considering a trajectory with γ 	= 0 and a direct treatment eﬀect of α,
we can consider a trajectory with γ = 0 and a direct treatment eﬀect of α + βγ. This
will simplify the calculations for Σθˆi . Since formula (2.6) represents Σθˆi when Zi = 0,
it should provide a good approximation when Σθˆi is similar between the two treatment
groups. To see the relationship between mi, tij and Σθˆi , let’s consider the alternative
trajectory with γ = 0. Equation (2.6) then simpliﬁes to
Σθˆi = ΣθRi
TWiRiΣθ, (2.7)
and
Σθˆi = ΣθQΣθ =
Σθ
⎛
⎜⎝
∑mi
j=1
∑mi
k=1 Wijk
∑mi
j=1
∑mi
k=1 tikWijk∑mi
j=1
∑mi
k=1 tijWijk
∑mi
j=1
∑mi
k=1 tijtijWijk
⎞
⎟⎠Σθ. (2.8)
When the trajectory is linear. Wijk is the element in the jth row and kth column
of Wi. Now we decompose Vi as PiDgiPi
T , where Pi is an mi × mi matrix with
orthonormal columns, and Dgi is a diagonal matrix with non-negative eigenvalues. Let
Pijk denote the element of the jth row and kth column of Pi, and Dgij denotes the
element in the jth row and jth column of Dgi . Then the diagonal elements of Q in
(2.8) can be expressed as
mi∑
j=1
mi∑
k=1
Wijk =
mi∑
j=1
D−1gij
(
mi∑
k=1
Pijk
)2
, (2.9)
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and
mi∑
j=1
mi∑
k=1
tijtijWijk =
mi∑
j=1
D−1gij
(
mi∑
k=1
tikPijk
)2
. (2.10)
We can see that both equations (2.9) and (2.10) are sums of mi non-negative ele-
ments, and thus are non-decreasing functions of mi. Equation (2.10) is also positively
associated with tij, implying a larger variance with longer follow-up period or with
longitudinal data collected at a later stage of the trial. However, we should keep in
mind that some subjects may have failed or are censored due to early termination. If
we schedule most data collection time point towards the end of the study, mi could be
reduced signiﬁcantly in many subjects. An ideal data collection strategy should take
into account drop-out and failure rates and balance tij and mi for a ﬁxed maximum
follow-up period.
The maximum follow-up period is usually preﬁxed due to timeline or budget con-
straints. We can observe more events with a longer follow-up and the increase in power
is likely to be more signiﬁcant due to an increased number of events. With a preﬁxed
follow-up period, the most important decision is perhaps to describe an optimal num-
ber of data collection points. Here, we speculate that the power would reach a plateau
as mi increases. The number of data collection points required to reach the plateau
is likely to be related to the degree of the polynomial in the trajectory function. A
lower order polynomial may require smaller mi. We investigated the power assuming
an unknown Σθ for diﬀerent mi in simulation studies. Results are summarized in Table
2.2 for a linear trajectory, and in Table 2.3 for a quadratic trajectory. We note that
longitudinal data, Yij, is missing after the event occurs or after the subject is censored.
Therefore mi varies among subjects. Let mx denote the scheduled, or maximum num-
ber of data collection points if the subject has not had an event and is not censored at
the end of the follow-up period. In the simulation studies described in Tables 2.2 and
2.3, mx was assumed to be the same for all subjects, and tij was equally spaced. In the
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linear trajectory simulation studies, we further assumed that the longitudinal data was
also collected when the subject exits the study due to an event or censoring, so that
each subject would have at least 2 measurements (baseline and end of study). In the
quadratic trajectory simulation studies, the longitudinal data was also collected when
the subject exited the study before their ﬁrst post-baseline scheduled measurement.
Therefore, Ri in equation (2.7) was not the same for all subjects. Some had diﬀerent
numbers of measurements; and some had measurements at diﬀerent tij’s. This results
in a diﬀerent Σθˆi for each subject. A weighted average of Σθˆi ’s can be used for the
sample size calculation. For a ﬁxed mx, the weighted average can be calculated as
mx∑
m=1
ξmΣθRm
T (Imσ
2
e +RmΣθR
T
m)
−1RmΣθ, (2.11)
where ξm is the % of non-censored subjects who have m measurements of the lon-
gitudinal data, Im is the m × m identity matrix, and Rm is the R matrix with m
measurements, Rm =
⎛
⎜⎜⎜⎜⎜⎜⎜⎝
1 t1 . . . t1p
1 t2 . . . t2p
...
...
. . .
...
1 tm . . . tmp
⎞
⎟⎟⎟⎟⎟⎟⎟⎠
. tk in the Rm matrix should represent
the mean measurement time of the kth measurement in the subjects who had m mea-
surements if not all measurments are taken at a ﬁxed timepoint.
In the 2nd to the last column of Tables 2.2 and 2.3, we present the calculated power
based on the maximum Σθˆi instead of a weighted average of Σθˆi ’s. The maximum
Σθˆi = ΣθR
T
mx(Imxσ
2
e + RmxΣθR
T
mx)
−1RmxΣθ. The simulation set up in Tables 2.2
and 2.3 is the same as in Section 2.3.4. The longitudinal data Yij was simulated via a
normal distribution with mean θ0i + θ1itij + γZi (linear), or θ0i + θ1itij + θ2it
2
ij + γZi
(quadratic), and variance σ2e . Yij was set to be missing after an event or censoring
occurred.
When the measurement error is relatively small and non-systematic, the two-step
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TABLE 2.2: Power for estimating β by maximum number of data collection points
(mx) and size of σ
2
e - linear trajectory
Power for Estimating β a
Calculated with Calculated with
σ2e mx βˆ Empirical Maximum Σθˆi Weighted Average Σθˆi
b
True trajectory 0.2098 87.1 86.0 a
0.09 6 0.2080 86.6 85.4 82.7
0.09 5 0.2075 85.8 85.3 82.6
0.09 4 0.2071 86.3 85.1 82.7
0.09 3 0.2076 86.4 84.9 82.9
0.09 2 0.2065 85.3 84.6 83.3
0.64 6 0.1960 76.3 82.2 75.9
0.64 5 0.1978 76.9 81.6 75.5
0.64 4 0.1939 74.8 80.8 74.9
0.64 3 0.1972 75.0 79.6 74.4
0.64 2 0.1967 74.0 77.4 74.4
1 6 0.1919 71.9 80.5 72.2
1 5 0.1918 71.8 79.7 71.5
1 4 0.1917 69.7 78.5 70.7
1 3 0.1940 70.1 76.8 69.9
a Calculated with Σθi
aβ was estimated using the two-step inferential approach (Tsiatis et al. 1995). Empirical power
was based on 1000 simulations, each with 100 subjects per arm. Minimum follow-up time is 0.75
years (9 months), and maximum follow-up time is 2 years. The event time is simulated from an
exponential distribution with λ0 = 0.85, α = 0.3, γ = 0.1, β = 0.2, E(θ0i) = 0, E(θ1i) = 3.,
V ar(θ0i) = 1.2, Var(θ1i) = 0.7, and Cov(θ0i, θ1i) = 0 (the same simulated data used in Row 4 of
Table 2.1).
bPower based on weighted average of Σθˆi .
inferential approach yields nearly unbiased estimates of the longitudinal eﬀect. The
number of data collection points did not seem to be critical when the trajectory is
linear as long as each subject had at least two measurements of the longitudinal data.
There is a slight decrease in power when mx < 5 and σ
2
e is large. When the trajectory
is quadratic, mx plays a more important role. The power for estimating β decreases as
mx decreases. Smaller numbers of measurements (mx < 4) can also lead to a biased
estimate of the longitudinal eﬀect and result in a signiﬁcant loss of power. The eﬀect
of mx on estimates and power is more signiﬁcant when σ
2
e is large. Note that when
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TABLE 2.3: Power for estimating β by maximum number of data collection points
(mx) and size of σ
2
e - quadratic trajectory
Power for Estimating β a
Calculated with Calculated with
σ2e mx βˆ Empirical Maximum Σθˆi Weighted Average Σθˆi
b
True trajectory 0.2212 91.6 90.6 a
0.09 10 0.2117 90.0 90.2 88.0
0.09 7 0.2102 89.5 90.0 88.0
0.09 5 0.2098 89.0 89.9 88.2
0.09 4 0.2014 89.3 89.8 88.4
0.09 3 0.1720 89.1 89.6 88.4
0.25 10 0.2135 89.7 89.5 86.1
0.25 7 0.2104 88.2 89.2 85.8
0.25 5 0.2089 86.7 88.8 85.8
0.25 4 0.2038 86.9 88.5 85.9
0.25 3 0.1621 86.6 88.0 85.8
0.81 10 0.2041 84.7 87.6 81.0
0.81 7 0.1984 81.5 86.6 79.7
0.81 5 0.2021 80.3 85.4 79.0
0.81 4 0.1818 79.1 84.7 78.8
0.81 3 0.1402 74.9 83.3 78.3
a Calculated with Σθi
aβ was estimated with the two-step inferential approach (Tsiatis et al. 1995). Empirical power
was based on 1000 simulations, each with 100 subjects per arm. Minimum follow-up time is 0.75
years (9 months), and maximum follow-up time is 2 years. The event time is simulated from an
exponential distribution with λ0 = 0.85, α = 0.3, γ = 0.1, β = 0.22, θi = (0, 2.5, 3)
T , and
Σθ = diag (1.2, 0.7, 0.8).
bPower based on weighted average of Σθˆi .
σ2e = 0, Σθˆi reduces to Σθ, and is unrelated to mx. The eﬀect of mx comes from the
magnitude of reducing the contribution of the within subject variability, σ2e . If we have
a very accurate and reliable measurement instrument, we can reduce the number of
repeated measurements and can still obtain unbiased estimates and maximum power.
The power calculation under the assumption of known Σθ or perfect data collection
(maximum Σθˆi) can result in a signiﬁcant over-estimate of the power especially when
σ2e is large. We next demonstrate that if we use the weighted average of Σθˆi ’s, we can
obtain a good estimate of power based on formula (2.4).
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Example 1 from Table 2.2: For the scenario with σ2e = 0.64 and mx = 2, we observed
that the mean measurement time for the subjects who had an event in the simulated
data is about 0.5 years. We used R2 =
⎛
⎜⎝ 1 0
1 0.5
⎞
⎟⎠ to calculate Σθˆ instead of setting
R2 =
⎛
⎜⎝ 1 0
1 2
⎞
⎟⎠, which assumes that the 2nd measurement was taken at 2 years. As a
result, the power based on formula (2.4) changed from 77.4% to 74.4%, which is much
closer to the empirical power of 74.0%. We used the mean measurement time in the
non-censored subjects, because the power calculation is mainly based on the number
of events. In practice, we need to make certain assumptions about tk based on the
median survival and length of the follow-up period.
Example 2 from Table 2.3: For demonstration, we chose the scenario with σ2e =
0.81 and mx = 4. In this example, the 2nd measurement was taken at 0.45 years
(on average) in subjects who had only 2 measurements. For subjects who had more
than 2 measurements, longitudinal data was collected at scheduled time points of 0,
0.5, 1, and 1.5. Therefore, R2 =
⎛
⎜⎝ 1 0 0
1 0.45 0.20
⎞
⎟⎠, R3 =
⎛
⎜⎜⎜⎜⎝
1 0 0
1 0.5 0.25
1 1 1
⎞
⎟⎟⎟⎟⎠, and
R4 =
⎛
⎜⎜⎜⎜⎜⎜⎜⎝
1 0 0
1 0.5 0.25
1 1 1
1 1.5 2.25
⎞
⎟⎟⎟⎟⎟⎟⎟⎠
. A weighted average of the Σθˆi ’s was calculated based on
formula (2.11). The resulting power is 78.8% instead of 84.7%, which is close to the
empirical power of 79.1%.
For trajectories that are quadratic or higher, it is important to schedule data collec-
tion to ensure mi is large enough for a reasonable proportion of subjects. For example,
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when the trajectory is quadratic and only a small proportion of subjects had 3 mea-
surements of the longitudinal data (mx = 3 in Table 2.3), we obtain a very biased
estimate of β.
2.5 Sample Size Determination for the Treatment
Eﬀect
Using the same model as speciﬁed in Section 2.3, the overall treatment eﬀect is βγ+α.
Thus the null hypothesis is H0: βγ + α = 0. Following the framework of Schoenfeld
(1983), we show that Schoenfeld’s formula can be extended to a joint modeling study
design by taking into account the additional parameters β and γ. The number of events
required for a one-sided level α˜ test with power β˜, assuming the hazard and trajectory
follow (2.1) and (2.2) in Section 2.2, is given by
D =
(zβ˜ + z1−α˜)
2
p1(1− p1)(βγ + α)2 , (2.12)
where p1 is the % of patients assigned to treatment 1 (Zi = 1). Properties of the
random eﬀects in the trajectory do not play a signiﬁcant role in the sample size and
power determination for the overall treatment eﬀect at the design stage. However,
correct assumptions must be made with regard to the overall treatment eﬀect (βγ+α).
If the longitudinal eﬀect is a biomarker, α and βγ should have the same sign (aggregated
treatment eﬀect). We acknowledge that under the proposed longitudinal and survival
model, the ratio of the hazard functions of the two treatment groups will be non-
proportional, as the trajectory is time-dependent. However, the method of using the
partial likelihood can readily be generalized to allow for non-proportional hazards. It
is unlikely that the proportional hazard assumption is ever exactly satisﬁed in practice.
When the assumption is violated, the coeﬃcient estimated from the model will be the
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“average eﬀect” over the range of time observed in the data (Allison 1995). Thus the
sample size formula developed using the partial likelihood method should provide a
good approximation of the power for estimating the overall treatment eﬀect in a joint
modeling setting.
The simulation studies presented in Table 2.4 show that formula (2.12) works ap-
proximately well in the two-step inferential approach when the primary objective is to
investigate the overall treatment eﬀect. The power is not sensitive to Σθ, and works
well with diﬀerent sizes of β and γ. We show in Sections 2.6 and 2.7 that the two-
step inferential approach and the full joint likelihood approach yield similar unbiased
estimates of the overall treatment eﬀect and have similar eﬃciency.
2.6 Biased Estimates of the Treatment Eﬀect When
Ignoring the Longitudinal Trajectory
When a treatment has an eﬀect on the longitudinal process (i.e., γ 	= 0 in equation
(2.2)) and the longitudinal process is associated with survival (i.e., β 	= 0 in equation
(2.1)), the overall treatment eﬀect on the time-to-event is (βγ+α). Thus, it is obvious
that ignoring the longitudinal process in the proportional hazards model would result
in a biased estimate of the treatment eﬀect on survival. When the longitudinal process
is not associated with the treatment (i.e, γ = 0 in equation (2.2)), it is not obvious that
ignoring the longitudinal trajectory in the proportional hazards model would result in
an attenuated estimate of the hazard ratio for the treatment eﬀect on survival (i.e.,
bias towards the null). This attenuation is known in the econometrics literature as the
attenuation due to unobserved heterogeneity (Horowitz 1999, Abbring et al. 2007), and
has been discussed in the work by Gail et al. (1984.
We demonstrated in simulation studies (Table 2.5) that the bias associated with
ignoring the longitudinal eﬀect is related to the size of β in the joint modeling setting.
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TABLE 2.4: Validation of formula (2.12) for testing the overall treatment eﬀect α+βγ
Power for Estimating
Overall Treatment Eﬀect βγ + α
β γ V ar(θ0i) V ar(θ1i) Cov(θ0i, θ1i) Empirical
a Calculated b
0.3 -0.1 1.2 0.7 0.2 69.2 67.2
0.3 -0.4 1.2 0.7 0.2 85.8 85.9
0.3 -0.8 1.2 0.7 0.2 96.7 97.1
0.3 -1.2 1.2 0.7 0.2 99.4 99.6
0.1 -0.4 1.2 0.7 0.2 65.8 62.7
0.4 -0.4 1.2 0.7 0.2 92.3 92.6
0.8 -0.4 1.2 0.7 0.2 98.7 99.8
0.3 -0.4 1.2 1 0.2 86.2 85.9
0.3 -0.4 1.2 1.5 0.2 86.4 85.9
0.3 -0.4 1.2 2 0.2 86.5 85.9
0.3 -0.4 1.2 4 0.2 85.5 85.9
0.4 -0.4 1.2 0.7 -0.8 92.7 92.6
0.4 -0.4 1.2 0.7 -0.4 92.2 92.6
0.4 -0.4 1.2 0.7 0.4 91.4 92.6
0.4 -0.4 1.2 0.7 0.8 92.0 92.6
aEmpirical power was based on the two-step inferential approach in 1000 simulations, each with
150 subjects per arm. Minimum follow-up time is 0.75 years (9 months), and maximum follow-up
time is 2 years. The event time is simulated from an exponential distribution with λ0 = 0.85,
α = −0.3, E(θ0i) = 0, and E(θ1i) = 3. The longitudinal data is measured at years 0, 0.5, 1, 1.5 and
at exit with a linear trajectory and σ2e = 0.16.
bCalculated based on mean number of deaths from simulations and ﬁxed value of p1 = 0.5, β, γ,
and α.
2.7 The Full Joint Modeling Approach Versus the
Two-Step Inferential Approach
When the true trajectory is unknown, we examined two joint modeling approaches.
The ﬁrst one was a two-step inferential approach proposed by Tsiatis et. al. (1995),
which has been described in detail in previous sections. The second approach was based
on the full joint likelihood as speciﬁed in (2.3). Wulfsohn and Tsiatis (1997) developed
an EM algorithm of the model in (2.3) to obtain the parameter estimates. Guo and
Carlin (2004) develop a fully Bayesian version and implemented it via Markov chain
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TABLE 2.5: Eﬀect of β on the estimation of direct treatment eﬀect on survival (α)
based on diﬀerent models
λi(t) = λ0(t) exp(αZi) λi(t) = λ0(t) exp{β(θ0i + θ1i)t + αZi}
exp(αˆ)a based on exp(αˆ) based on exp(αˆ) based on exp(αˆ) based on full
Cox partial known two-step approach joint likelihood
β likelihood trajectory (partial likelihood) b as speciﬁed in (2.3)
0 0.668 (0.062) 0.667 (0.062) 0.667 (0.062) 0.667 (0.062)
0.4 0.697 (0.057) 0.668 (0.053) 0.667 (0.053) 0.667 (0.053)
0.8 0.755 (0.063) 0.670 (0.050) 0.673 (0.050) 0.668 (0.051)
1.2 0.800 (0.068) 0.670 (0.049) 0.684 (0.051) 0.668 (0.051)
aexp(αˆ) is the average value based on 1000 simulations, each with 200 subjects per arm. Minimum
follow-up time is set to be 0.75 years (9 months), and maximum follow-up time is set to be 2 years.
The baseline hazard is assumed constant with λ0 = 0.85, and the true direct treatment eﬀect on
survival α = −0.4 (i.e., HR = 0.670).
bLongitudinal data is measured at years 0, 0.5, 1, 1.5 and at exit with a linear trajectory and
σ2e = 0.16
Monte Carlo (MCMC) methods using the WinBUGS software. We used a standard SAS
procedure, NLMIXED, which ﬁts nonlinear mixed models by maximizing an approxi-
mation to the likelihood integrated over the random eﬀects using a dual quasi-Newton
algorithm (SAS Online Documentation for Version 9.1.3). Standard deviations for the
estimates are based on the 2nd derivatives of the log-likelihood function. Data was sim-
ulated based on a fully parametric exponential model with constant baseline hazard.
The two-step inferential approach is based on Cox’s partial likelihood. It is expected
that the full joint modeling approach using exactly the same exponential model will
have more eﬃciency over the partial likelihood model. However, in practice, we rarely
use a fully parametric model with constant hazard to analyze the time-to-event data.
To have a fair comparison of eﬃciency, we simulated survival data based on a piecewise
exponential model with two time intervals in which the baseline hazard changed from
λ01 to λ02 at time tq. We used the same parameters in both periods, and therefore, β is
the same. Five repeated measurements of the longitudinal data were simulated based
on the θ’s. The measurements were set to be missing after an event or censoring.
We show in Table 2.6 that the full joint modeling approach based on a paramet-
ric exponential model is more eﬃcient than the two-step inferential approach based
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TABLE 2.6: Comparison of the two-step inferential approach with the full joint
modeling approach in testing β and the overall treatment eﬀect
λ01 λ02 Two-Step Approach Full Joint Modeling
[0, 0.75] (0.75, ∞) Parameter Estimates (StdErr) Power Estimates (StdErr) Power
0.85 0.85 βˆ 0.203 (0.074) 79.9 0.206 (0.054) 96.4
αˆ + βˆγˆ 0.319 (0.162) 50.0 0.321 (0.163) 49.6
0.85 0.65 βˆ 0.204 (0.075) 78.4 0.164 (0.053) 85.5
αˆ + βˆγˆ 0.322 (0.164) 50.8 0.328 (0.164) 51.5
0.85 0.45 βˆ 0.208 (0.077) 76.2 0.108 (0.053) 52.0
αˆ + βˆγˆ 0.326 (0.167) 49.7 0.339 (0.167) 51.6
0.65 0.85 βˆ 0.208 (0.073) 80.10 0.248 (0.054) 99.4
αˆ + βˆγˆ 0.323 (0.168) 49.1 0.318 (0.170) 45.7
Note: Estimates were based on 1000 simulations, each with 100 subjects per arm. Survival
time was simulated with a piecewise exponential model, minimum follow-up time is 0.75 years (9
months), and maximum follow-up time is 2 years. α = 0.3, γ = 0.1, β = 0.2, E(θ0i) = 0, E(θ1i) = 3,
Var(θ0i) = 0.7, Var(θ1i) = 1.2, Cov(θ0i, θ1i) = 0.2, and σ2e = 0.16 A maximum of 5 repeated
measurements were simulated with missing data after an event or censoring. Both analyses assumed
an unknown Σθ.
on Cox’s partial likelihood. However, the full joint exponential model is sensitive to
whether the baseline hazard is constant over time. When this is true, it yields an unbi-
ased estimate of β; but yields biased estimates of β when the constant baseline hazard
assumption is violated. In this case, it overestimates the trajectory eﬀect when the
baseline hazard increases after time tq. Furthermore, it underestimates the trajectory
eﬀect when the baseline hazard decreases after time tq. The larger the diﬀerence be-
tween the two baseline hazards, the larger the bias. The two-step inferential approach
may be more robust, although less eﬃcient. The impact is smaller when testing the
overall treatment eﬀect. Both approaches have similar eﬃciency, but the misspeciﬁed
exponential joint model yields a slightly biased estimate of the treatment eﬀect. This
ﬁnding is not surprising, as it corresponds to known theory between parametric and
semi-parametric modeling. A retrospective power analysis from a real study data is
provided in Section 2.10, Appendix B.
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Wulfsohn and Tsiatis (1997) found that the asymptotic standard error of βˆ when us-
ing the joint estimation procedure is slightly larger than that from the two-step model.
It was suggested that it might be because the random eﬀects were assumed to be inﬂu-
enced by the uncertainty in the estimated trajectory parameters, and more variability
is incorporated. Therefore, although the full joint estimation approach should be more
eﬃcient as compared to the two-step model, since it uses information more eﬃciently.
It may not turn out to be the case in real data settings if the real data violate the
modeling assumptions. Wulfsohn and Tsiatis (1997) cited earlier work concerning bi-
ased estimates of the trajectory eﬀect when using the two-step model (slightly towards
the null) and suggested that the estimate from the joint model is further away from
the null, and therefore more likely to reduce the bias. We found in the simulation
studies that the trajectory eﬀect can be over-estimated or under-estimated in the fully
parametric joint model if the model assumptions, such as a constant baseline hazard in
the case of the exponential model, is violated. The two step model in this case may be
more robust. Further studies are needed to compare the two joint modeling approaches
and other parametric or semi-parametric models. These topics are beyond the primary
focus of this paper.
2.8 Discussion
In this paper, we have provided a closed form sample size formula for estimating the
eﬀect of the longitudinal data on time-to-event and discussed optimal data collection
strategies. The number of events required to study the association between event time
and the longitudinal process for a given follow-up period is related to the covariance
matrix of the random eﬀects (coeﬃcients for the p-polynomial), within subject vari-
ability, frequency of repeated measurements, and timing of the repeated measurements.
Only a few parameters are required in the sample size formula. The median event time
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and mean follow-up time are needed to calculate the truncated moments. The mean
follow-up time can be approximated by the average of the minimum and maximum
follow-up times under the assumption of uniform censoring. A structured covariance
matrix can be used when we do not have prior data to determine each element of Σθ.
More robust estimates can be achieved by assuming an unknown Σθ. An unknown Σθ
requires further assumptions about the number and timing of repeated measurements,
and the percentage of subjects who are still on-study at each scheduled measurement
time. This is exactly what the researchers should consider during the design stage. It
is helpful to consider a few diﬀerent scenarios and compare them with the calculated
power. When the measurement error is small, estimates with known Σθ also provide a
good approximation of power.
We have also extended Schoenfeld’s (1983) sample size estimation formula to the
joint modeling setting for estimating an overall treatment eﬀect. When the longitudinal
data is associated with treatment, the overall treatment eﬀect is an aggregated eﬀect
on time-to-event directly and on the longitudinal process. When the longitudinal data
is not associated with treatment, ignoring the longitudinal data will still lead to atten-
uated estimates of the treatment eﬀect due to unobserved heterogeneity. The degree
of attenuation depends on the degree of the association between the longitudinal data
and time-to-event data. Use of a joint modeling analysis strategy leads to reduction
of bias and increase in power in estimating the treatment eﬀect. However, joint mod-
eling is not yet commonly used in designing clinical trials. Most applications of joint
modeling in the literature focus on estimating the eﬀect of the longitudinal outcome
on time-to-event.
Finally, we mention here that missing longitudinal data in practice is typically
nonignorably missing in the sense that the probability of missingness depends on the
longitudinal variable that would have been observed. In order to examine the robust-
ness of our sample size formulas to nonignorable missingness, we conducted several
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simulation studies in which the empirical power was computed under a noningnorable
missing data mechanism using a selection model. Under several scenarios, our cal-
culated powers based on the proposed sample size formulas were quite close to the
empirical powers, therefore illustrating that our sample size formulas are quite robust
to nonignorable missing data. Developing exact sample size formulas in the presence
of nonignorable missing data is a very challenging problem that requires much further
research.
One of the limitations of this method is that we did not consider the treatment-
by-time interaction in the model, which precludes the random slopes model. Although
simulations and distributional assumptions of the random eﬀects in this paper were
based on a Gaussian distribution, such distributional assumptions are not required for
the formula. It may be applied to more general joint modeling design settings. To the
best of our knowledge, this is the ﬁrst paper that addresses trial design aspects using
joint modeling.
2.9 Appendix A: Derivation of Sample Size For-
mula for Testing the Trajectory Eﬀect
The sample size formula was derived from the score test following Schoenfeld’s (1983)
framework. Let D denote the number of subjects who had the event in the trial, and
let N denote the number of subjects in the trial. let Ti and Ci denote the event and
censoring times, respectively; Si = min(Ti, Ci) and Δi = I(Ti ≤ Ci). Let Zi be a
treatment indicator, and let Xi(u) be the longitudinal process (also referred to as the
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trajectory in the paper) at time u ≥ 0. Deﬁne
ei{(Xk(Si))q} =∑N
k=1 I(Sk ≥ Si)exp{βXk(Si) + αˆZk}(Xk(Si))q∑N
k=1 I(Sk ≥ Si)exp{βXk(Si) + αˆZk}
and
Gi{(Xk(Si))q} =
∑N
k=1 I(Sk ≥ Si)exp{αˆZk}(Xk(Si))q∑N
k=1 I(Sk ≥ Si)exp{αˆZk}
,
where Xk(u) = θ0k + θ1ku+ θ2ku
2 + · · ·+ θpkup + γZk, and q = 1, 2, . . . . For the hazard
function h(S) = λ0(S)exp{βX(S) + αZ}, the partial likelihood is given by
Li =
{
exp{βXi(Si) + αZi}∑N
k=1 I(Sk ≤ Si)exp{βXk(Si) + αZk}
}Δi
.
The score statistic for Cox’s partial likelihood can be expressed as
Sscore =
N−
1
2
∑
i∈D Xi(Si)−Gi{Xk(Si)}{
N−1
∑
i∈D Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
} 1
2
.
Now, rewrite the score statistic as
Sscore =
N−
1
2
∑
i∈D(Xi(Si)− ei{Xk(Si)}){
N−1
∑
i∈D Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
} 1
2
+
N−
1
2
∑
i∈D(ei{Xk(Si)} −Gi{Xk(Si)}){
N−1
∑
i∈D Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
} 1
2
.
∑
i∈D(Xi(Si) − ei{Xk(Si)}) is the score function of the partial likelihood, and thus,
the numerator of the ﬁrst term is asymptotically normal with mean 0 and variance
N−1
∑
i∈D ei{(Xk(Si))2}−(ei{Xk(Si)})2. As in Schoenfeld (1983) and Ewell & Ibrahim
(1997), consider alternatives, which are location shifts of known distribution functions,
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such that β is O(n−
1
2 ). As ei{(Xk(Si))q} → Gi{(Xk(Si))q} when β → 0, the ﬁrst term
→ N(0, 1) when β → 0.
Expanding the numerator of the 2nd term in a Taylor’s series about β = 0 shows
that
ei{Xk(Si)} −Gi{Xk(Si)} ≈
β
{
Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
}
.
The 2nd term approaches
β
{
D∑
i=1
{Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
} 1
2
.
Since Zk is a ﬁxed treatment indicator and assuming that each treatment group is large,
Gi{(Xk(Si))q} =
1
N
∑N
k=1 I(Sk ≥ Si)exp{αˆZk}(Xk(Si))q
1
N
∑N
k=1 I(Sk ≥ Si)exp{αˆZk}
→ E {I(Sk ≥ Si)(Xk(Si))
q}
E {I(Sk ≥ Si)} . (2.13)
When β → 0, Sk is independent of the θk’s and I(Sk ≥ Si) is independent of Xk(Si)
conditional on Si, thus (2.13) → E {(Xk(Si))q}. Then
Gi{(Xk(Si))2} − (Gi{Xk(Si)})2 →
E
{
(Xk(Si))
2
}− {E(Xk(Si))}2 = Var{Xk(Si)}
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as β → 0. It follows that
βD
1
2
{
1
D
∑
i∈D
{Gi{(Xk(Si))2} − (Gi{Xk(Si)})2
} 1
2
→ βD 12
{
1
D
∑
i∈D
Var(Xk(Si))
} 1
2
= βD
1
2
{
1
D
∑
i∈D
(1 Si . . . S
p
i )Σθ (1 Si . . . S
p
i )
T
} 1
2
= βD
1
2
{
1
D
∑
i∈D
Si Σθ S
T
i
} 1
2
, (2.14)
where Σθ is the covariance matrix of (θ0k θ1k . . . θpk). Note that
1
D
∑
i∈D
Sqi =
N
D
1
N
∑
i∈D
T qi → E {I(T ≤ t¯f )T q} /τ,
where τ = D
N
is the event rate, and t¯f is the mean follow-up time in all subjects. It
is a truncated moment of T q, as we do not observe all Ti’s. Therefore (2.14) above
converges to
β
{
Dσ2s
} 1
2 ,
where
σ2s = Var(θ0k) +
p∑
j=1
Var(θjk)E{I(T ≤ t¯f )T 2j}/τ
+ 2
p∑
j=0
p∑
l>j
Cov(θjk, θlk)E{(I ≤ t¯f )T j+l}/τ, (2.15)
and p is the degree of polynomial in the trajectory. For example, when p = 1 (linear
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trajectory),
σ2s = Var(θ0k) + Var(θ1k)E{I(T ≤ t¯f )T 2}/τ
+ 2Cov(θ0k, θ1k)E{I(T ≤ t¯f )T}/τ.
Thus, the score statistic, Sscore, is asymptotically normal with unit variance and
mean equal to β {Dσ2s}
1
2 as D →∞. It follows that the number of events required for
a one-sided level α˜ test with power β˜ is given by
D =
(zβ˜ + z1−α˜)
2
σ2sβ
2
,
where σ2s is deﬁned in (2.15).
2.10 Appendix B: Retrospective Power Analysis for
the ECOG Trial E1193
To illustrate parameter selection and the impact of incorporating Σθˆi in the power
calculation, we apply the sample size calculation formula retrospectively based on pa-
rameters obtained from the Eastern Cooperative Oncology Group (ECOG) E1193 trial
(Sledge et al. 2003). E1193 is a phase III cancer clinical trial of doxorubicin, pacli-
taxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy
for metastatic breast cancer. Patients receiving single-agent doxorubicin or paclitaxel
crossed over to the other agent at time of progression. Quality of life (QOL) was
assessed using the FACT-B scale at two time points during induction therapy. The
FACT-B includes ﬁve general subscales (physical, social, relationship with physician,
emotional, and functional), as well as a breast cancer-speciﬁc subscale. The maximum
possible score is 148 points. A higher score is indicative of better qualify of life. In this
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TABLE 2.7: Parameter Estimates with Standard Errors for the E1193 Data
Cox Model with
Parameters Treatment Only Two-Step Model Joint Model
Overall Treatment (αˆ + βˆγˆ) 0.251 (0.1302) 0.261 (0.1304) 0.271 (0.1413)
αˆ 0.245 (0.1362)
γˆ -0.073 (0.1291)
βˆ -0.277 (0.0708) -0.445 (0.1184)
subset analysis, we analyzed overall survival after entry to the crossover phase (sur-
vival after disease progression), and its association with treatment and quality of life.
A total of 252 patients entered the crossover phase and have at least one QOL mea-
surement, 124 patients crossed over from paclitaxel to doxorubicin (median survival is
13.0 months in this subgroup), 128 patients crossed over from doxorubicin to paclitaxel
(median survival is 14.9 months in this subgroup). The data we used is quite mature,
with only 2 subjects who crossed over to doxorubicin and 6 subjects who crossed over to
paclitaxel were censored. We applied the Cox model with treatment eﬀect only, the two
step model incorporating the two QOL measurements, and the proposed joint model as
speciﬁed in Section 2 of the paper, to analyze the treatment eﬀect and eﬀect of QOL.
Since there are only two QOL measurements, we ﬁt a linear mixed model. To satisfy
the normality assumption for the longitudinal QOL, we transformed the observed QOL
to QOL
1
2 . Results are report in Table 2.7.
Treatment eﬀects are similar between the two-step model and the joint model. The
diﬀerence in the QOL eﬀect, βˆ, is similar to that of Wulfsohn and Tsiatis (1997).
They reported a slightly larger βˆ and standard error in the joint model as compared
to the two-step model. In Section 6 of this paper, we used simulation studies to
demonstrate that βˆ is sensitive to whether the constant hazard assumption is sat-
isﬁed in the joint model we used. We obtained the following parameter estimates
for the retrospective power calculation: The median overall survival is 13.56 months,
Σθ
1
2 =
⎛
⎜⎝ 0.8417 0
0 0.0025
⎞
⎟⎠, σe = 0.7188, the mean measurement time for the ﬁrst
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FIGURE 2.1: Retrospective Power Analysis for the E1193 Trial with Known and Un-
known Σθ
QOL is 0.052 months, the mean measurement time for the 2nd QOL is 2.255 months,
and 35% of the subjects had only one QOL measurement. If we assume a known Σθ,
the power with 243 events and β = 0.3 is 98%. When we assume an unknwon Σθ and
use a weighted average of Σθˆi , the power reduced to 90%. The relationship between
sample size and power for both known and unknown Σθ cases are illustrated in Figure
2.1.
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CHAPTER 3
Sample Size Determination in
Shared Frailty Models for
Multivariate Time-to-Event Data
3.1 Introduction
The need to study or analyze multiple correlated time-to-event data arises in many
experimental designs and observational studies. For example, we may wish to make
inferences about survival in individuals who share a common genetic makeup, or who
share a common environment. We may also study the time to occurrence of diﬀerent
non-lethal diseases within the same individual. Subjects may experience the event
of interest more than once (recurrent events) during the course of the study. The
shared frailty model is quite popular for analyzing multivariate time-to-event data
(Oakes 1989, Peterson 1998, Duchateau et al. 2003, Cook and Lawless 2007, Zeng et
al. 2009, Rondeau 2010). A frailty, a concept introduced by Vaupel et al. (1979), is
an unobservable random eﬀect. For multivariate time-to-event data, it represents the
unobserved covariates shared by correlated event times. The most common model for
a frailty is the shared frailty model, where the common random eﬀect (frailty) has a
multiplicative eﬀect on the individual hazard. It is assumed that conditional on the
frailty, the event times are independent and thus have hazards that are similar to the
univariate model.
One major consideration in frailty models is the choice of the frailty distribution.
Clayton (1978) and Oakes (1982) ﬁrst considered frailty models with a gamma distri-
bution for the frailty. In the gamma frailty model, which is the model considered in this
paper, the frailty can be easily integrated out and thus the observed-data likelihood has
a closed form. Hougaard discussed multivariate failure models, where the frailty fol-
lows a positive stable distribution (Hougaard 1986a) or a power variance family (PVF)
distribution (Hougaard 1986b). Whitmore and Lee (1991) proposed a model with an in-
verse Gaussian frailty and constant hazard. The compound Poisson frailty model was
considered by Aalen (Aalen 1988, 1992). The Lognormal frailty model (McGilchrist
and Aisbett 1991, Korsgaard et al. 1998) has gained popularity recently especially
in Bayesian models. The selection of the family of frailty distributions, based on the
properties of the various models was discussed by Hougaard (1995).
Besides the shared frailty model, other frailty models have been considered to handle
more complex multivariate time-to-event data. Price and Manatunga (2001) considered
the use of cure frailty models to analyze leukaemia recurrence with a cured fraction.
The nested frailty model that accounts for the hierarchical clustering of the data by
including two nested random eﬀects is considered by Rondeau et al. (2006). Most re-
cently, joint frailty models for modeling recurring events and death have been proposed
(Rondeau et al. 2007). There has been very limited research that focus on design issues
for studies involving multivariate time-to-event data. Manatunga and Chen (2000) con-
sidered sample size determination for survival outcomes in cluster-randomized studies
with small cluster sizes, and provided a sample size formula using bivariate marginal
distributions for the survival times. Jiang (1999) considered design aspects of group
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sequential trials with recurrent time-to-event endpoints, allowing frailty of event fre-
quencies in a Poisson process. Jiang’s approach is an extension of Cook and Lawless’
(1996) idea of using robust pseudo-score statistics that do not necessarily have an inde-
pendent increments structure. Jiang’s paper focused on the asymptotic joint distribu-
tion of the sequential test statistics and derived an iterative algorithm for calculating
stopping boundaries and planning sample size. Xia and Hoover (2007) also considered
a group sequential procedure for comparative Poisson trials based on exact conditional
binomial distributions for the number of events. The method of Manatunga and Chen
(2000) cannot be applied to clinical trials with general multivariate time-to-event data.
The Poisson model can only be applied to recurrent event times and focuses on the
number of recurrent events given a ﬁxed follow-up period instead of focusing on time
to each recurrent event. Sample size determination methodology in studies with gen-
eral multivariate time-to-event data is greatly lacking in the literature. In this paper,
we develop a sample size determination method for the shared Gamma frailty model
to investigate the treatment eﬀect on multivariate correlated event times. A closed
form sample size formula is derived. Time-to-recurrent events is discussed as a special
case in the general multivariate time-to-event setting. We ﬁrst consider sample size
determination for testing a common treatment eﬀect on all correlated event times in
Section 3.2. In Section 3.3, we consider sample size determination for testing the treat-
ment eﬀect on one time-to-event while treating the other event times as nuisance, and
compare the power from a multivariate frailty model to that of a univariate parametric
or semi-parametric survival model.
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3.2 Sample Size Determination for Testing a Com-
mon Treatment Eﬀect
3.2.1 The Shared Frailty Model
Assume that the event time for the ith subject and the jth event type (i = 1, . . . , N, j =
1, . . . , K) is drawn from a Weibull frailty model with shape parameter γ and frailty ωi.
The hazard function of the event time for the ith subject and the jth event type, tij, is
λij(tij) = ωiγt
γ−1
ij exp(β0 + βjxij),
where xij denotes the explanatory variable for subject i and the jth event type, and β0
and βj are the intercept and the coeﬃcient of the explanatory variable xij, respectively.
We consider a model with gamma frailty ωi, and thus f(ωi) =
θθ
Γ(θ)
ωθ−1i exp(−θωi), with
mean 1 and variance 1
θ
. Conditional on ωi, the survival times are assumed independent.
Thus the observed-data likelihood is given by
L(θ, β) =
n∏
i=1
∫ ∞
0
K∏
j=1
[
ωiγt
γ−1
ij exp(β0 + βjxij)exp(−ωitγijexp(β0 + βjxij))
]νij
×
[
exp(−ωitγijexp(β0 + βjxij))
]1−νij θθ
Γ(θ)
ωθ−1i exp(−θωi)dωi, (3.1)
where νij is the censoring indicator (which equals 0 for censoring, 1 otherwise), and tij
denotes the event time for subject i for the jth event type. After ωi is integrated out
in (3.1), the observed-data likelihood is given by
L(θ, β) =
n∏
i=1
Γ(θ + Di)
Γ(θ)
(
θ
θ + tγi .(β)
)θ(
γ
θ + tγi .(β)
)Di
× exp
( K∑
j=1
νij(β0 + βjxij)
) K∏
j=1
t
(γ−1)νij
ij , (3.2)
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where Di =
∑K
j=1 νij and t
γ
i .(β) =
∑K
j=1 t
γ
ijexp(β0 + βjxij).
3.2.2 Sample Size Determination for Testing a Common
Treatment Eﬀect
For ease of exposition, let treatment be the only explanatory variable and therefore
xi = xi1 = xi2 = · · · = xiK in this particular setting. When testing a common treatment
eﬀect, we have β = β1 = · · · = βK . And the null hypothesis, H0, is β = 0. We assume
that the follow-up time for the study is Bf , which determines how many events will be
observed at the end of the study, and therefore is an important design parameter. In
an actual clinical trial, Bf is diﬀerent for diﬀerent subjects. For the purpose of sample
size determination, we can use the mean follow-up time. It is shown in Appendix A
that the score statistic, Sscore, of likelihood (3.2) is asymptotically normal with unit
variance and mean equal to β
√
nΨ as n → ∞. It follows that the total number of
subjects required for a one-sided level α˜ test with power β˜ is given by
n =
(zβ˜ + z1−α˜)
2
Ψβ2
, (3.3)
where
Ψ =
K∑
m=0
(θ + m)
(
K
m
)
Em,t[Cm(t)− C2m(t)], (3.4)
Cm(t) =
eβ0(
∑m
j=1 t
γ
j + (K −m)Bγf )
θ + eβ0(
∑m
j=1 t
γ
j + (K −m)Bγf )
, (3.5)
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and
Em,t[Cm(t)− C2m(t)]
=
∫ Bf
0
. . .
∫ Bf
0
∫ ∞
Bf
. . .
∫ ∞
Bf
[Cm(t)− C2m(t)]
f(t1, . . . , tK)dtK . . . dtm+1dtm . . . dt1. (3.6)
The quantities
(
K
m
)
and f(t1, . . . , tK) in equation (3.6) denote the number of unique
combinations of m non-censored times out of K possible event times, and the density
function of (t1, . . . , tK) respectively. Based on the observed-data likelihood in (3.2), we
have
f(t1, . . . , tK) =
Γ(θ + K)
Γ(θ)
θθγK
(
1
θ + eβ0
∑K
j t
γ
j
)θ+K
eKβ0
K∏
j=1
tγ−1j . (3.7)
Em,t[Cm(t)− C2m(t)] can be easily evaluated numerically. Many mathematical and
statistical packages have numerical integration procedures for evaluating multidimen-
sional integrals. The package “cubature” in R carries out adaptive multidimensional
integration over hypercubes. It is based on the algorithms described in Genz and Ma-
lik (1980), and Berntsen et al. (1991). R code to calculate Em,t[Cm(t) − C2m(t)] and
power for K = 3 is provided in Appendix B. eβ0 in (3.2) and (3.7) is the event rate, or
number of events per time unit. In most conﬁrmatory clinical trials, there are only two
treatment arms. If the treatment covariate, xi, is coded as {0, 1}, eβ0 will be the event
rate in the control arm. If we make any assumptions about β0, observations from the
control arm would not contribute to the power determination. To take into account
variation from both arms and for ease of exposition, we used the {−1, 1} coding so
that the event rate is exp(β0−β) for the control arm and exp(β0+β) for the treatment
arm. The hazard ratio under this coding will be exp(2β). The formula in (3.3) can
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then be rewritten with respect to the hazard ratio as
n =
4(zβ˜ + z1−α˜)
2
Ψ(log(HR))2
,
where “HR” refers to the hazard ratio and the calculation of Ψ follows from (3.4), (3.5)
and (3.6).
In addition to the hazard ratio and the mean follow-up time, the power of the test
is determined by the size of Ψ. Larger Ψ leads to higher power and Ψ increases as θ
increases. This implies that smaller variation in the frailty, that is, a smaller correlation
between the event times requires a smaller sample size to achieve the desired power.
Since 0 < Cm(t) < 1, Cm(t) − Cm(t)2 is maximized when Cm(t) = 0.5, the shape
parameter γ contributes little to the power.
3.2.3 Simulation Studies
We carried out simulation studies to verify the sample size determination algorithm
described in Section 3.2.2. We ﬁrst simulate the frailty, ωi based on a one-parameter
gamma distribution. Conditional on ωi, we simulate independent event times based
on a Weibull survival model. The censoring time is independently simulated from a
uniform distribution on [4, 12]. The mean follow-up time, Bf , is considered to be 8
months for the calculation of Em,t[Cm(t) − C2m(t)]. If tj is greater than the censoring
time, Bi, the subject will be censored at Bi. We assume that the sample size for each
simulation is 300 and the subjects were randomized to two treatment arms in a 1:1 ratio.
Table 4.1 summarizes the empirical power and the power that is calculated based on
the formula and algorithm described in Section 3.2.2 for diﬀerent model parameters.
Empirical power refers to the % of simulated datasets, out of 1, 000 simulated datasets,
that has a p-value smaller than 0.05 for estimating β. The simulated studies show
very good agreement in power determination based on our formula as compared to the
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TABLE 3.1: Comparison of Empirical Power and Calculated Power for Testing a
Common Treatment Eﬀect with Diﬀerent Model Parameters
Power
θ exp(β0) exp(2β) (HR) γ K Empirical Calculated
2 0.05 0.706 2 3 85.0 85.0
1 0.05 0.706 2 3 64.8 64.4
1.5 0.05 0.706 2 3 76.7 77.5
2 0.05 0.810 2 3 42.9 44.1
2 0.02 0.706 2 3 80.1 81.9
2 0.05 0.706 4 3 86.8 85.5
2 0.05 0.706 2 5 92.7 91.9
empirical power. It also shows that the power increases as K, the number of event
types, increases which is likely due to increases of the total number of events. Besides
exp(β0) = 0.05, % censoring also depends on
1
θ
, the variance of the frailty. When θ = 2
and exp(β0) = 0.05, approximately 19% of the observations are censored. When θ = 2
and exp(β0) = 0.02, approximately 40% of the observations are censored.
3.2.4 Recurrent Events
Recurrent event times are a special case of multivariate time-to-event data. The formula
and algorithm discussed in Section 3.2.2 can be applied to testing a common treatment
eﬀect for recurrent events with minor adjustments. There are two diﬀerences we should
consider when applying the shared frailty model for recurrent events: i) time to the ﬁrst
event during the study period is deﬁned from study entry. Subsequent recurrent events
will start from the end of the previous event time. For some of the event types, it may
be diﬃcult to determine when the event ends. Therefore, it is common to consider the
time of the previous event as the baseline for the subsequent recurrent event, ii) event
m can only occur if there is event m− 1.
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The observed-data likelihood based on the recurrent-event model is given by
L(θ, β) =
n∏
i=1
Γ(θ + Di)
Γ(θ)
(
θ
θ + tγi .(β)
)θ(
γ
θ + tγi .(β)
)Di
× exp
( Ki∑
j=1
νij(β0 + βjxij)
) Ki∏
j=1
t
(γ−1)νij
ij ,
where Di =
∑Ki
j=1 νij and t
γ
i .(β) =
∑Ki
j=1 t
γ
ijexp(β0 + βjxij). Compared to the observed-
data likelihood function in (3.2) of Section 3.2.1, a subscript is added to K, allowing
the number of events to diﬀer for diﬀerent subjects. Ψ for the sample size formula (3.3)
in Section 3.2.2 is also modiﬁed as
Ψ =
max(Ki)∑
m=0
(θ + m)Em,tm+1 [Cm(t)− C2m(t)].
The factor
(
K
m
)
is removed because recurrent events can only occur in sequential
order. Em,t[Cm(t)−C2m(t)] is replaced with Em,tm+1 [Cm(t)−C2m(t)], which means that
the expectation is taken with respect to {t1, . . . , tm+1, 0 ≤ m ≤ Ki}, as subjects who
have m events can be censored for the (m + 1)st event. Unlike events that can occur
simultaneously, we cannot assume the same follow-up time for all m recurrent events.
If the total follow-up time is assumed to be Bf , and the mean event time is t¯, the
follow-up time for the mth event will be Bf − (m− 1)t¯. For example, the mean follow-
up time for the ﬁrst event is Bf , the mean follow-up time for the 2nd event is Bf − t¯,
and the mean follow-up time for the 3rd event is Bf − 2t¯, etc. Denoting the follow-up
time for the mth event as Bfm, m = 1, 2, . . . , we have
Cm(t) =
eβ0
(∑m
j=1 t
γ
j + B
γ
fm
)
θ + eβ0
(∑m
j=1 t
γ
j + B
γ
fm
) ,
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and
Em,tm+1 [Cm(t)− C2m(t)]
=
∫ Bf1
0
. . .
∫ Bfm
0
∫ ∞
Bf(m+1)
[Cm(t)− C2m(t)]f(t1, . . . , tm+1)dtm+1 . . . dt1.
3.3 Testing the Treatment Eﬀect on One Time-to-
Event While Treating the Other Event Times
as Nuisance
3.3.1 Simulation Studies
Although multiple events can occur, one is often interested in testing whether a treat-
ment has an eﬀect for one particular event. Also, it may not be reasonable to assume
a common treatment eﬀect on all event times. When the interest is only on a speciﬁc
time-to-event, a common practice is to use a univariate Cox model or Weibull model
for the time-to-event of interest without considering other event times in the statis-
tical design. In this section, we compare the empirical power of testing β1 from the
multivariate frailty model with that of a univariate model based on simulation studies.
Assumptions for simulating the data are similar to what is described in Section 3.2.3
except that each event time was simulated with a diﬀerent βj based on the Weibull
model described in Section 3.2.1. In our simulation study, we consider the impact of
the following parameters on the empirical power, which is deﬁned as the % of p-values
less than 0.05 out of 1,000 simulated datasets:
1. The correlation between the event times, which is reﬂected by the variance of the
frailty, 1
θ
. Large values of θ, that is, a small variance of the frailty implies less
correlation between the event times. When θ →∞, this represents independence
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between the event times.
2. The size of the βj’s (j 	= 1), and
3. The baseline event rate which will result in a diﬀerent percentage of censoring
between the event of interest and the nuisance event times.
The results are summarized in Table 4.2 and Table 4.3. When the data is correlated,
the multivariate frailty model yields unbiased estimates of β1, β2 and β3. The power
from the frailty model is substantially higher compared to that of the univariate Weibull
or Cox model when the variance of the frailty is large, that is, when the event times
are highly correlated. When θ = 0.5, the Pearson correlation coeﬃcient between t1
and t2 (or t3) is approximately 0.85 in simulated data without censoring. This level of
correlation results in a 23% diﬀerence in power between the multivariate frailty model
and the univariate model. The diﬀerence decreases quickly as the time-to-event data is
less correlated, and disappears when θ = 5, which translates into a Pearson correlation
coeﬃcient of 0.18 in simulated data without censoring. When the event times are
independent, the performance of the univariate model is the same as the multivariate
frailty model. When the event times are correlated, the loss in power seems to be
mainly due to an attenuated biased estimate of β1. The Cox model yields a more
biased estimate of β1, but only a small diﬀerence in the empirical power. The impact
of the size of β2 and β3 on the power seems to be small. In Table 4.3, we consider
diﬀerent baseline event rates so that the percentage of censoring can be diﬀerent for
the K event times. We also change the shape parameter in the Weibull distribution to
examine its impact on the diﬀerence in power between the multivariate model and the
univariate model, since the shape parameter is related to the censoring rate based on
eβ0 . The power for testing β1 from the multivariate frailty model is similar to that of
the univariate model when the variance of the frailty is small regardless of the censoring
rate. When the event times are more highly correlated, there is a larger diﬀerence when
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TABLE 3.2: Estimating and Testing β1 in Multivariate Time-to-Events with K = 3
and eβ0 = 0.05 Using Diﬀerent Models
Simulation
Parameters Frailty Modelb Weibull Modelb Cox Model
Na θ eβ1 eβ2 eβ3 eβˆ1 Power (%) eβˆ1 Power (%) eβˆ1 Power (%)
600 0.5 0.8 0.9 0.6 0.802 76.3 0.837 53.6 0.910 52.6
500 1 0.8 0.2 0.3 0.797 86.7 0.820 78.9 0.868 78.2
500 1 0.8 5.0 3.3 0.797 84.3 0.820 76.9 0.868 76.6
500 1 0.8 1 1 0.800 85.0 0.822 75.8 0.870 74.5
400 2 0.8 0.2 0.3 0.800 88.6 0.812 84.6 0.846 83.6
400 2 0.8 5.0 3.3 0.798 89.6 0.810 88.0 0.845 86.4
400 2 0.8 1 1 0.799 89.4 0.811 85.8 0.846 84.9
300 3 0.8 0.2 0.3 0.799 82.7 0.807 81.8 0.834 80.8
300 3 0.8 5.0 3.3 0.801 83.6 0.809 81.6 0.834 79.8
300 3 0.8 1 1 0.799 85.4 0.806 82.5 0.833 82.1
240 4 0.8 0.9 0.6 0.801 81.4 0.803 80.7 0.833 78.0
240 5 0.8 0.9 0.6 0.797 84.8 0.799 85.3 0.824 83.0
200 ∞c 0.8 0.9 0.6 0.824 81.9 0.800 84.6 0.798 83.0
aOverall sample size.
bThe shape parameter for the Weibull distribution is 2 in simulated data.
cEvent time is simulated independently with diﬀerent eβ0 and γ.
the censoring rate is low in t1. The impact of censoring on t2 or t3 is small. Even when
t1 has a high censoring rate and t2, t3 have a high event rate, the multivariate model
does not seem to “borrow” more strength from the other time-to-event data.
3.3.2 Sample Size Determination for Testing β1
When considering diﬀerent treatment eﬀects on {t2, . . . , tK}, one needs to make as-
sumptions regarding K − 1 parameters. This is usually diﬃcult at the design stage.
Even if we can make reasonable assumptions on these parameters based on prior data,
assumptions on known {β2, . . . , βK} will result in an over-estimate of the power, com-
pared to a model that treats {β2, . . . , βK} as unknown parameters. In Section 3.3.1,
we show that the sizes of β2 and β3 have a minimal eﬀect on the power when testing
β1, but the variance of the frailty has a signiﬁcant impact. Instead of using the mul-
tivariate frailty model, we suggest using a univariate frailty model that will take into
account the frailty but will eliminate {β2, . . . , βK} from the formula. We believe that
incorporating the frailty in a univariate model will correct the bias from the classical
53
TABLE 3.3: Estimating and Testing β1 Using Diﬀerent Models by Diﬀerent Baseline
Event Rates
Simulation Parameters Frailty Model Weibull Model Cox Model
% t1 not % t2 not % t3 not
Na γ censored censored censored eβˆ1 Power (%) eβˆ1 Power (%) eβˆ1 Power (%)
When variance of the frailty = 1
3
300 1 90.2 74.6 80.6 0.798 85.6 0.808 83.9 0.836 82.5
500 1 43.3 26.5 21.2 0.800 84.9 0.806 85.1 0.815 84.8
400 1 43.2 74.6 80.7 0.800 74.6 0.808 74.0 0.816 73.9
300 2 86.6 73.6 78.7 0.801 83.0 0.809 82.2 0.837 81.3
500 2 43.3 23.0 18.5 0.799 82.9 0.806 83.2 0.816 82.5
500 2 43.3 73.6 78.8 0.797 86.8 0.803 85.9 0.814 85.7
When variance of the frailty = 1
500 1 78.5 69.2 72.9 0.805 89.2 0.828 77.1 0.875 76.0
600 1 38.3 23.3 19.2 0.800 82.9 0.814 78.4 0.836 78.5
600 1 38.3 69.1 72.9 0.808 79.3 0.818 76.1 0.838 75.8
500 2 75.9 67.9 71.1 0.802 89.9 0.822 77.4 0.872 75.7
600 2 38.2 20.4 16.8 0.802 77.0 0.817 74.9 0.841 74.9
600 2 38.1 68.0 71.1 0.801 77.9 0.816 74.6 0.840 74.4
500 2 75.9 20.4 16.8 0.799 83.7 0.822 77.3 0.872 76.6
Notes: K = 3 with β1 = 0.8, β2 = 0.2, β3 = 0.3.
aOverall sample size.
univariate Weibull model or Cox model, and thus will result in only small power loss
when the event times are highly correlated.
Based on the observed-data likelihood for the univariate frailty model,
L(θ, β1) =
n∏
i=1
Γ(θ + νi1)
Γ(θ)
(
θ
θ + tγi1e
β0+β1xi
)θ(
γ
θ + tγi1e
β0+β1xi
)νi1
× exp(νi1(β0 + β1xi))t(γ−1)νi1i1 ,
the sample size formula we derived in Section 3.2.2 can be modiﬁed for testing the
hypothesis that H0: β1 = 0. The score statistic, Sscore, for testing β1 is also asymp-
totically normal with unit variance and mean equal to β1
√
nΨ1 as n → ∞. The total
number of subjects required for a one-sided level α˜ test with power β˜ is given by
n =
(zβ˜ + z1−α˜)
2
Ψ1β21
, (3.8)
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where
Ψ1 =
1∑
ν1=0
(θ + ν1)Eν1,t1 [C1(t1)− C21(t1)], (3.9)
and
C1(t1) =
eβ0tγν11 B
γ(1−ν1)
f
θ + eβ0tγν11 B
γ(1−ν1)
f
. (3.10)
Similarly,
E0,t1 [C1(t1)− C21(t1)] =
∫ ∞
Bf
[C1(t1)− C21(t1)]f(t1)dt1,
E1,t1 [C1(t1)− C21(t1)] =
∫ Bf
0
[C1(t1)− C21(t1)]f(t1)dt1,
and
f(t1) =
Γ(θ + 1)
Γ(θ)
(
θ
θ + tγ1e
β0
)θ(
γ
θ + tγ1e
β0
)
× exp(β0)t(γ−1)1 .
In Table 3.4, we provide the power based on the above formula and the empirical
power from the multivariate frailty model as speciﬁed in (3.1) where both β2 and β3
are considered unknown, as in Tables 4.2 and 4.3 of Section 3.3.1. The approximation
is very good even when the correlation between the event times is as high as 0.67. The
formula tends to underestimate the power when the event times are highly correlated
(a Pearson correlation coeﬃcient greater than 0.67).
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TABLE 3.4: Estimating and Testing β1: Empirical and Calculated Power by Diﬀerent
Correlation Between Event Times (K = 3, γ = 2, eβ0 = 0.05, and eβ1 = 0.8)
Simulation Parameters Empirical Power (%) Calculated
Na θ Correlationb eβ2 eβ3 Multivariate Frailty Model Power (%)
600 0.5 0.85 0.9 0.6 76.3 68.3
500 0.8 0.75 0.9 0.6 80.1 75.6
460 1 0.67 0.2 0.3 81.1 78.4
460 1 0.67 0.9 0.6 79.9 78.4
400 1.5 0.51 0.2 0.3 82.6 82.5
400 1.5 0.51 0.9 0.6 83.8 82.5
340 2 0.41 0.2 0.3 84.3 82.0
340 2 0.41 0.9 0.6 83.1 82.0
320 2.5 0.33 0.2 0.3 83.3 83.6
320 2.5 0.33 0.9 0.6 82.7 83.6
300 3 0.29 0.2 0.3 82.7 84.0
300 3 0.29 0.9 0.6 84.5 84.0
240 4 0.22 0.9 0.6 81.4 79.4
aOverall sample size.
bPearson correlation coeﬃcient between t1 and t2/t3 prior to censoring. It is the average in two
treatment groups.
3.3.3 A Real Data Example
In this section, we re-analyze data from a real longitudinal study where multiple highly
correlated event times were collected, and compare p-values from the multivariate frailty
model with that of the univariate Cox model. The main purpose is to verify the con-
clusion from Section 3.3.1, with a real data analysis, that the multivariate frailty model
is more powerful than a univariate model when the event times are highly correlated.
This is a prospective, population-based cardiovascular health study to assess
whether polymorphisms in the C-reactive protein (CRP) gene are associated with
plasma CRP, carotid intima-media thickness and cardiovascular disease events (Lange
et al. 2006). In this study, 4 tag single-nucleotide polymorphisms SNPs) (1919A/T,
2667G/C, 3872G/A, 5237A/G) were genotyped in 3941 white participants≤ 65 years; 5
tag SNPs (plus 790A/T) were genotyped in 700 black participants ≤ 65 years. Subjects
were followed up between 1989 and 2003 for cardiovascular events (myocardial infarc-
tion, stroke, and CVD mortality) with a median follow-up time of 13 years. Event
rates range from 11% to 14% in whites, from 9% to 12% in blacks. We re-tested the
association between SNP 3872 genotypes and the three event times using the frailty
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model described in Section 3.2.1, and compared the conclusion (p-value) with that in
the original paper where the association was tested using a univariate Cox model. In
the original paper (Lange et al. 2006), SNP 3872 was found to be associated with
CVD mortality, but no association with stroke was evident in white participants based
on a Cox proportional hazard model. SNP 3872 was not found to be associated with
myocardial infarction, stroke or CVD mortality in black participants. The database we
obtained has the same number of subjects but has slightly diﬀerent number of events,
likely due to timing of data cutoﬀ. SNP 3872 genotype AA seems to be associated with
risk of stroke and CVD mortality, while genotypes AA or AG seem to be associated
with risk of myocardial infarction. For demonstration purposes, we investigate associ-
ation between risk of stroke and genotype AA in white participants, and association
between risk of myocardial infarction and genotypes AA or AG in black participants.
In white participants, we found a very strong association between the risk of stroke
and SNP 3872 genotype AA. The estimated hazard ratio is 0.66 (p-value = 0.008) from
the frailty model. The estimate of the frailty variance is 3.4 (θ = 0.2942), suggesting
a very strong correlation between the event times. The estimated hazard ratio is 0.74
(p-value = 0.068) from the Cox model, consistent with results reported in the paper. In
black participants, we also found a signiﬁcant association between the risk of myocardial
infarction and SNP genotypes AA or AG. The estimated hazard ratio is 0.50 (p-value
= 0.029) from the frailty model. The estimated variance of the frailty is 4.5. The
estimated hazard ratio is 0.54 (p-value = 0.044) from the Cox model.
This example conﬁrms ﬁndings from our simulation study in Section 3.3.1. When
the primary analysis is based on a multivariate frailty model, sample size calculation
based on the univariate Cox model can greatly over-power the study. The sample size
formula provided in Section 3.3.2 provides a better approximation.
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3.4 Discussion
In this paper, we derived a closed form sample size determination formula for testing a
common treatment eﬀect in a shared Gamma frailty model based on a Weibull hazard
for the event times. This is applicable to highly correlated events, such as recurrent
events, where a common treatment eﬀect can be assumed. The results from Table
4.1 and Table 4.2 suggest that testing a common treatment eﬀect when the treatment
eﬀects are similar is more powerful than testing a single event time alone. This is intu-
itive, as the total number of events is much larger when testing a common treatment
eﬀect. Therefore, the typical sample size determination for univariate survival analysis
will underestimate the power for the multivariate survival analysis. The Weibull hazard
covers a wide range of parametric event time distributions with a diﬀerent shape pa-
rameter, and is adequate for modeling monotonic hazard rates. However, the Weibull
family is inappropriate if the hazard rate is u-shaped or n-shaped. If a u-shaped or
n-shaped hazard rate is expected, the sample size determination formula provided in
this paper may not be applicable.
For recurrent events, the methodology described in Section 3.2.4 has certain limita-
tions. As the expected value of [Cm(t)−C2m(t)] is based on large sample theory, it will
be problematic if a few subjects had many more recurrent events compared to the rest
of the subjects. If this is expected, the following two solutions are recommended: 1) we
can ignore these subjects in the sample size determination. As the number of subjects
involved is small, it should have limited impact on the power of the study. 2) Use an al-
ternative model. Earlier work by Cook & Lawless (1996) and Jiang (1999) considered a
sample size determination algorithm based on a Poisson process with frailty. The model
focused on counting the number of events given a ﬁxed follow-up period. Compared
to the multivariate time-to-event model, the Poisson model has its own limitations. It
can result in a signiﬁcant loss of power due to censoring as it is almost impossible to
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have a ﬁxed follow-up period for every subject.
In Section 3.3, we discussed whether the power can still be improved by using a
multivariate frailty model when the interest is to test the treatment eﬀect on t1, as
compared to a univariate survival model. We found that the diﬀerence depends on the
variance of the frailty, that is, the correlation between the event times. When the event
times are highly correlated, such as progression-free survival and overall survival in
some oncology studies, the multivariate frailty model will have substantial advantages
over the univariate model. The univariate survival model can lead to an attenuated
biased estimate of β1 and thus can result in a substantial loss of power. However, when
the correlation is small, there is no obvious advantage of using the multivariate frailty
model. We found in our simulation studies that when the correlation is ≤ 0.2, the
advantage of the frailty model is diminished. However, this cutoﬀ point likely depends
on other model parameters, such as the Weibull shape parameter and baseline hazard.
We found that the power diﬀerence between the multivariate model and the uni-
variate model is also related to the event rates, with larger diﬀerences when the event
rate is high for t1. This can be explained by the fact that the correlation between
the event times is reduced due to censoring even though the correlation between event
times without censoring is high. However, in the real data example, we demonstrated
a signiﬁcant diﬀerence in the estimates of the hazard ratio and p-values even when the
event rates are extremely low. The frailty also has a signiﬁcant impact on the event
rate even when eβ0 is ﬁxed. The number of subjects required to test the same treatment
eﬀect seems to decrease as θ increases, that is, when the event times are less correlated.
This is simply due to higher event rates when θ is large when eβ0 is ﬁxed.
Sample size determination based on the typical univariate model will greatly un-
derestimate the power when the event times are highly correlated. Unfortunately, it
is diﬃcult to make any assumptions about βj (j = 2, . . . , K) at the design stage. We
suggest an algorithm based on a univariate frailty model taking into account the frailty,
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which induces correlation in the multivariate time-to-event data. We found that the
approximation provided in formula (3.8) to (3.10) provides a very good estimate of the
power from the multivariate model even when the correlation coeﬃcient between the
event times is as high as 0.67. Although this cutoﬀ probably also depends on other
model parameters, it is likely true that the method proposed here will be reasonably
good for moderate to high correlation between event times. The proposed method is
simple and makes no assumptions about the size of the other nuisance βj’s. Further
simulation studies will be needed to assess the performance of the method on other
models with a wider range of model parameters.
3.5 Appendix A: Derivation of Sample Size For-
mula for Testing a Common Treatment Eﬀect
on Multivariate Time-to-event
Let l be the log likelihood of (3.2). Then
∂l
∂β
=
n∑
i=1
−(θ + Di)
xie
β0+βxi
∑K
j=1 t
γ
ij
θ + eβ0+βxi
∑K
j=1 t
γ
ij
+ xiDi,
and
∂2l
∂β2
=
n∑
i=1
−(θ + Di)
[
x2i e
β0+βxi
∑K
j=1 t
γ
ij
θ + eβ0+βxi
∑K
j=1 t
γ
ij
−
(
xie
β0+βxi
∑K
j=1 t
γ
ij
θ + eβ0+βxi
∑K
j=1 t
γ
ij
)2]
.
Deﬁne
Ci(ti) =
eβ0
∑K
j=1 t
γ
ij
θ + eβ0
∑K
j=1 t
γ
ij
,
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and
ei(ti) =
eβ0+βxi
∑K
j=1 t
γ
ij
θ + eβ0+βxi
∑K
j=1 t
γ
ij
.
The score statistic is given by
Sscore =
∑n
i=1 xiDi − (θ + Di)xiCi(ti)√∑n
i=1(θ + Di)x
2
i [Ci(ti)− C2i (ti)]
.
Now, rewrite the score statistic as
Sscore =
∑n
i=1 xiDi − (θ + Di)xiei(ti)√∑n
i=1(θ + Di)x
2
i [Ci(ti)− C2i (ti)]
+
∑n
i=1(θ + Di)xi[(ei(ti)− Ci(ti)]√∑n
i=1(θ + Di)x
2
i [Ci(ti)− C2i (ti)]
.
The quantity
∑n
i=1 xiDi − (θ + Di)xiei(ti) is the score function of the likelihood, and
thus, the numerator of the ﬁrst term is asymptotically normal with mean 0 and variance
n−1
∑n
i=1(θ+Di)x
2
i [ei(ti)−e2i (ti)]. As in Schoenfeld (1983) and Ewell & Ibrahim (1997),
consider alternatives which are location shifts of known distribution functions, such that
β is O(n−
1
2 ). As ei(ti)→ Ci(ti) when β → 0, the ﬁrst term → N(0, 1) when β → 0.
Expanding the numerator of the 2nd term in a Taylor’s series about β = 0 shows
that
n∑
i=1
(θ + Di)xi[(ei(ti)− Ci(ti)] ≈ β
n∑
i=1
(θ + Di)x
2
i [Ci(ti)− C2i (ti)].
Here, xi is a ﬁxed treatment indicator, and we assume that there are two treatment
groups with xi = {−1, 1}. For large n, the 2nd term can be approximated by
√
nβ
√√√√1
n
n∑
i=1
(θ + Di)[Ci(ti)− C2i (ti)].
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Since Di = {0, 1, . . . , K},
1
n
n∑
i=1
(θ + Di)[Ci(ti)− C2i (ti)]
=
1
n
n0∑
i∈{Di:0}
(θ + 0)[Ci(ti)− C2i (ti)] +
1
n
n1∑
i∈{Di:1}
(θ + 1)[Ci(ti)− C2i (ti)]
+ · · ·+ 1
n
nK∑
i∈{Di:K}
(θ + K)[Ci(ti)− C2i (ti)],
where nm, m = {0, 1, . . . , K}, is the number of subjects with m events. Assume that
the censoring time, Bf , is the same for all subjects, which implies that any time-to-event
greater than Bf will be censored at Bf . Then if subject i has m events,
Ci(ti) =
eβ0(
∑m
j=1 t
γ
ij + (K −m)Bγf )
θ + eβ0(
∑m
j=1 t
γ
ij + (K −m)Bγf )
.
Let Cm(t) be the population counterpart of Ci(ti) when the subject has m events,
that is,
Cm(t) =
eβ0(
∑m
j=1 t
γ
j + (K −m)Bγf )
θ + eβ0(
∑m
j=1 t
γ
j + (K −m)Bγf )
.
Then,
1
n
nm∑
i∈{Di:m}
(θ + m)[Ci(ti)− C2i (ti)]
→
(
K
m
)
Et
{
[Cm(t)− C2m(t)]I(t1 < Bf , . . . , tm < Bf , tm+1 ≥ Bf , . . . , tK ≥ Bf )
}
=
(
K
m
)∫ Bf
0
. . .
∫ Bf
0
∫ ∞
Bf
. . .
∫ ∞
Bf
[Cm(t)− C2m(t)]
f(t1, . . . , tK)dtK . . . dtm+1dtm . . . dt1,
where
(
K
m
)
denotes the number of unique combinations of m non-censored times out of
K possible event types, and f(t1, . . . , tK) is the joint density function of (t1, . . . , tK).
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Let Em,t[Cm(t) − C2m(t)] denote Et
{
[Cm(t) − C2m(t)]I(t1 < Bf , . . . , tm < Bf , tm+1 ≥
Bf , . . . , tK ≥ Bf )
}
. Then,
1
n
n∑
i=1
(θ + Di)[Ci(ti)− C2i (ti)]
→
K∑
m=0
(θ + m)
(
K
m
)
Em,t[Cm(t)− C2m(t)]
= Ψ.
It follows that the score statistic is asymptotically normal with unit variance and
mean equal to β
√
nΨ.
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CHAPTER 4
Flexible Stopping Boundaries When
Testing Diﬀerent Parameters at
Diﬀerent Interim Analyses in
Clinical Trials
4.1 Introduction
It is fundamental to have clinical trials that are properly designed to answer speciﬁc
scientiﬁc questions, such as whether the drug improves overall survival. Every trial
design is striving to answer this question with as much robustness and accuracy as
possible while involving the fewest number of patients, reasonable costs and the shortest
duration of time. Methodology for group sequential clinical trials has developed largely
during the past few decades so that a trial can be stopped early if there is strong
evidence of eﬃcacy during any planned interim analysis. Pocock (1977) ﬁrst proposed
that the crossing boundary be constant for all equally spaced analyses. O’Brien and
Fleming (1979) suggested that the crossing boundaries for the kth analysis, zc(k), be
changed over the total number of analyses K such that zc(k) = zOBF
√
K/k. In both
procedures, the number of interim analyses and the timing of the interim analyses
need to be pre-determined. The O’Brien-Fleming boundaries have been used more
frequently because they preserve a nominal signiﬁcance level at the ﬁnal analysis that
is close to that of a single test procedure. Earlier work by Haybittle and Peto (1971,
1976) in a less formal structure suggested the use of an arbitrarily large value for the
crossing boundary for each interim analysis, and the boundary for the ﬁnal analysis
should be determined such that the overall type I error rate be preserved. Wang and
Tsiatis (1987) examined a class of group sequential boundaries that yield approximately
optimal results with respect to minimizing the expected sample size.
The alpha spending function developed by Lan and DeMets (1983) over the course
of a group sequential clinical trial is a more ﬂexible group sequential procedure that
does not require the total number nor the exact time of the interim analyses to be
speciﬁed in advance. Other parametric alpha spending functions have been considered,
which include the gamma spending function (Hwang et al. 1990), and the rho spending
function (Kim & DeMets 1987, Jennison & Turnbull 2000). A high degree of ﬂexibility
has been well developed with respect to timing of the analyses and how much type I
error (alpha) to spend at each analyses. One concern about the alpha spending function
procedure is that one can change the frequency of the analyses as the results come closer
to the boundary. Later work by Lan and DeMets (1989) showed that if a Pocock-like
or O’Brien-Fleming like continuous spending function is adopted, the impact on the
overall alpha is very small. Proschan et al. (1992) also did a thorough research to
address the issue of changing the frequency of interim analyses.
Earlier development of the alpha spending function was based on the assumption
that the information accumulated between each interim analysis is statistically indepen-
dent. However, this assumption does not apply to longitudinal studies in a sequential
test of slopes for which the total information is unknown. Sequential analysis using the
linear random-eﬀects model suggested by Laird and Ware (1982) has been considered by
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Lee and DeMets (1991), and Wu and Lan (1992). There have been debates on whether
the alpha spending function can still be used since the independent increment structure
does not hold and the information fraction is unknown (Wei et al. 1990, Su & Lachin
1992). It was argued by DeMets and Lan (1994) that the alpha spending function can
still be used with a more complex correlation between successive test statistics. The key
to using the alpha spending function is being able to deﬁne the information fraction.
Although the correlation between successive test statistics will not be exactly known,
it can be estimated by a “surrogate” of the information fraction. Stopping boundaries
for studies that stop early to reject the null hypothesis H0 were generalized to studies
that stop early to reject either H0 or H1 (the alternative hypothesis) by Pampallona et
al. (1995, 2001).
The motivation of this paper came from a design of a phase III trial in patients with
glioblastoma multiforme (GBM). GBM is the most common and most aggressive type
of primary brain tumor in humans, and has the worst prognosis of any central nervous
system (CNS) malignancy, despite multimodality treatments. An innovative treatment
option that can provide any hope to these patients should be made available to the
medical society as early as possible, especially when a few patients from a small phase
II study had survived more than 12 months at the time. The treatment being studied
is a targeted therapy with little safety issues compared to most chemotherapies. Given
its orphan drug status, the investigator wishes to design the study using progression-
free survival (PFS) as the primary endpoint in the interim analysis, while using overall
survival as the primary endpoint to be tested at the ﬁnal analysis. The motivation for
this type of design is the low event rate for overall survival at early interim analysis
times while the PFS event rate is much more mature at these earlier interim analysis
times. Also, in recurrent event studies, one may be interested in examing diﬀerent
recurrent events at diﬀerent interim analyses. For example, at time of the ﬁrst interim
analysis, most subjects may have the ﬁrst occurrence of the event, while very few have
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the second occurrence. Thus, it would not be appropriate to use time to 2nd occurrence
as the primary endpoint. As time progresses, time to 2nd or 3rd occurrence may be of
interest to the investigator and may be a more appropriate primary endpoint at these
later analyses. Chen et al. (2003) considered a special case based on the log rank
statistic where mortality was used as the primary endpoint at interim analysis while a
composite endpoint was used as the primary endpoint at ﬁnal analysis.
With advances in medical research, such as in the area of biomarker discovery,
clinical study design is also becoming more complex. For example, in the case of a
good biomarker that is collected over time, the longitudinal data will be associated
with both the time-to-event and the treatment. There may be suﬃcient power to test
these associations at early interim analyses while testing the direct association between
the time-to-event and treatment may require a substantially larger sample size. In
this paper, we extend the alpha spending function methodology to derive stopping
boundaries when our interest focuses on examining diﬀerent endpoints (parameters) at
diﬀerent analysis times. Statistically, this is equivalent to testing diﬀerent hypotheses
at diﬀerent interim analyses. In Section 4.2, the newly derived stopping boundaries
are compared to the boundaries without changing the parameters, using the Pocock
and O’Brien-Fleming like spending functions proposed by Lan and DeMets (1983).
Applications to biviarate survival models and joint models of longitudinal and time-to-
event data are discussed in Sections 4.3 and 4.4. We close the article with a discussion
in Section 4.5.
4.2 Stopping Boundaries for Testing Diﬀerent Pa-
rameters at the Interim and Final Analysis
The alpha spending function is described in Section 1.4, and notations in this chapter
follow those in Section 1.4. In general, if diﬀerent interim analyses involve diﬀerent
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parameters, the covariance structure is unknown; and we cannot obtain the asymptotic
joint distribution of
(
Z(1), Z(2), . . . , Z(k)
)
. Thus, deriving zc(k) will be problematic.
When the parameters we are testing at the interim analysis and the ﬁnal analysis are
from the same likelihood function, however, the covariance is known and is computed
from the expected Fisher information matrix.
To make our ideas clear, let θ1 denote the parameter to be tested at the lth interim
analysis, and let θ2 be the parameter to be tested at the kth interim analysis. The
null hypotheses are H0: θ1 = θ01 for testing θ1, H0: θ2 = θ02 for testing θ2. Let
lk denote the log-likelihood at the kth analysis from nk independent samples, lk =
lnL(θ1, θ2|ynk). Further assume that Z(l) and Z(k) are the score statistics at the lth and
kth interim analysis, and the information accumulated between each interim analysis
is independent. Deﬁne
Sl =
∂ll
∂θ1
|θ1=θ01 , S∗k =
∂lk
∂θ2
|θ2=θ02 ;
Il = −E
[
∂2ll
∂θ21
]
|θ1=θ01 , I∗k = −E
[
∂2lk
∂θ22
]
|θ2=θ02 .
It can be shown that
Cov{Z(l), Z(k)} = E(Z(l)Z(k)) = E
(
SlS
∗
k√
IlI∗k
)
=
E{Sl(S∗l + S∗k−l)}√
IlI∗k
=
E{SlS∗l }+ E{SlS∗k−l}√
IlI∗k
=
E
(
∂ll
∂θ1
∂ll
∂θ2
)
|θ1=θ01,θ2=θ02√
IlI∗k
=
√
nl
nk
I12(θ01, θ02)√
I11(θ01)I22(θ02)
, (4.1)
where I12(θ01, θ02) is the oﬀ diagonal element of the expected Fisher information matrix,
and I11(θ01), I22(θ02) are the diagonal elements of the expected Fisher information
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matrix. Note that E{SlS∗k−l} = 0 when the k − l observations are independent of
the l observations (independent increments of information). Therefore, when we test
diﬀerent hypotheses at diﬀerent interim analyses, the stopping boundaries will not only
depend on the information fraction, they will also depend on the information matrix of
the two parameters under H0. Thus, there will not be one set of stopping boundaries
that can be used for all likelihood functions or all parameters. The investigators in this
case must derive their own stopping boundaries for diﬀerent study designs.
Let w = I12(θ01,θ02)√
I11(θ01)I22(θ02)
, it can be shown that
w =
E
(
∂l
∂θ1
∂l
∂θ2
)
√
E
((
∂l
∂θ1
)2)
E
((
∂l
∂θ2
)2) |θ1=θ01,θ2=θ02
=
Cov
(
∂l
∂θ1
, ∂l
∂θ2
)
√
Var
(
∂l
∂θ1
)
Var
(
∂l
∂θ2
) |θ1=θ01,θ2=θ02 ,
where l is the log-likelihood based on a sample of size 1. Thus w is the correlation
coeﬃcient of the score function, and |w| ≤ 1. Since the covariance matrix of the test
statistics (Z(1), Z(2), . . . , Z(k)) is positive deﬁnite, the value of w is also bounded by a
number that is ≥ −1. When we test the same parameter between the lth and the kth
interim analysis, w = 1. We next calculate diﬀerent stopping boundaries by assuming
diﬀerent values of w. In Table 4.1, we compare the boundaries computed from α1(t
∗)
and α2(t
∗), the O’Brien-Fleming-like, and the Pocock-like alpha spending functions
proposed by Lan & DeMets (1983). The comparison is made for a one-sided test with
signiﬁcance level α = 0.025, K = 5, and the test parameter is θ1 for j = 1, 2, θ2 for
j = 3, 4, 5 (j = 1, . . . , 5), and t∗j = j/5.
Note that between (j = 1, 2) and (j = 3, 4, 5), the value of w is still 1. The
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TABLE 4.1: One-sided Boundaries for Diﬀerent Values of w with α = 0.025 and
K = 5 (The test parameter is assumed to be θ1 for j = 1, 2, θ2 for j = 3, 4, 5, where
j = 1, . . . , 5, t∗j = j/5.)
O’Brien-Fleming Like Alpha Pocock Like Alpha
Spending Function α1(t
∗) Spending Function α2(t∗)
w zc(1) zc(2) zc(3) zc(4) zc(5) zc(1) zc(2) zc(3) zc(4) zc(5)
1 4.88 3.36 2.68 2.29 2.03 2.44 2.42 2.41 2.40 2.39
0.8 4.88 3.36 2.69 2.29 2.03 2.44 2.42 2.50 2.43 2.42
0.5 4.88 3.36 2.70 2.30 2.03 2.44 2.42 2.57 2.46 2.44
0 4.88 3.36 2.70 2.30 2.03 2.44 2.42 2.60 2.50 2.45
-0.5 4.88 3.36 2.70 2.30 2.03 2.44 2.42 2.60 2.50 2.45
-0.7 4.88 3.36 2.70 2.30 2.03 2.44 2.42 2.60 2.50 2.45
covariance matrix for (Z(1), . . . , Z(5))T is
⎛
⎜⎜⎜⎜⎜⎝
1
p
1/2
p
1/3w∗
p
1/4w∗
p
1/5w∗
p
1/2 1
p
2/3w∗
p
2/4w∗
p
2/5w∗
p
1/3w∗
p
2/3w∗ 1
p
3/4
p
3/5
p
1/4w∗
p
2/4w∗
p
3/4 1
p
4/5
p
1/5w∗
p
2/5w∗
p
3/5
p
4/5 1
⎞
⎟⎟⎟⎟⎟⎠,
where w∗ 	= 1. We can see that the covariance matrix can be partitioned into four sub-
matrices
⎛
⎜⎝ Σθ1 Σθ1,θ2
Σ′θ1,θ2 Σθ2
⎞
⎟⎠. Solving for (zc(1), . . . , zc(K)) in equation (1.6) requires
numerical integration. The quadrature method by Armitage et al (1969) cannot be
applied here with this covariance structure since the statistics are not the same in the
sequential procedure. The method solves the density function fn(sn) recursively based
on a recursive relationship between fn(sn) and fn−1(sn−1). Such a recursive relationship
is not available in our methodologic setup. Here, we used the adaptive integration
method by Genz (1992) to evaluate zc(k). Compared to a Monte Carlo algorithm
and the subregion adaptive algorithm, the adaptive integration method of Genz (1992)
reliably computes multivariate normal probabilities with as many as ten variables in
a few seconds. For example, the average absolute error for 6 variables ranged from
0.00016 for a constant covariance matrix to 0.00174 for a random covariance matrix
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TABLE 4.2: One-sided Boundaries for the 5th Analysis zc(5) When α = 0.025 and
K = 5 (The test parameter is assumed to be θ1 for j = 1 − 4, θ2 for j = 5, where
j = 1, . . . , 5, t∗j = j/5.)
w
Alpha Spending Function 1 0.8 0.5 0 -0.5 -0.7
O’Brien-Fleming Like Function, α1(t
∗) 2.03 2.13 2.19 2.23 2.23 2.23
Pocock Like Function, α2(t
∗) 2.39 2.54 2.64 2.70 2.70 2.70
(Genz 1992).
When we compare our boundaries to a group sequential procedure that do not
change parameters at diﬀerent interim analyses, the boundaries are very close when the
alpha spending function is α1(t
∗). However, the boundaries are substantially diﬀerent
when the alpha spending function is α2(t
∗).
We next consider a scenario where we change the parameter at the ﬁnal (5th)
analysis. Our stopping boundary for the ﬁrst 4 analyses will be the same as the ones
in Lan and DeMets (1983). The 5th boundary was calculated for diﬀerent values of w
(Table 4.2). The boundary is substantially diﬀerent than the Lan-Demets boundary.
This shows that when the parameter is changed when α is minimally spent prior to the
change, as in early interim analyses using α1(t
∗), the impact on the stopping boundaries
is small. The more α is spent prior to the change of the parameters, the more signiﬁcant
the impact is on the boundaries. In Table 4.3, we compare the boundaries computed
from α1(t
∗) and α2(t∗) for a one-sided α = 0.025 test with K = 2 and t∗j = j/2.
Tables 4.1, 4.2, and 4.3 conﬁrm these properties. If the test parameter is changed after
spending a substantial α, there is also a substantial penalty involved. There are also
cumulative penalties when the test parameter is changed more than once.
In practice, accurate assumptions about the size of w may be diﬃcult to make. In
this case, researchers can use more conservative boundaries by assuming a smaller w.
In cases when not much of the α has been spent at interim analyses when the test
parameter changes, the penalty involved is minimal.
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TABLE 4.3: One-sided Boundaries for Diﬀerent Values of w with α = 0.025, K = 2
and t∗j = j/2.)
O’Brien-Fleming Like Alpha Pocock Like Alpha
Spending Function α1(t
∗) Spending Function α2(t∗)
w zc(1) zc(2) zc(1) zc(2)
1 2.96 1.97 2.16 2.20
0.8 2.96 1.98 2.16 2.25
0.5 2.96 1.98 2.16 2.30
0 2.96 1.99 2.16 2.34
-0.5 2.96 1.99 2.16 2.34
-0.8 2.96 1.99 2.16 2.34
-1 2.96 1.99 2.16 2.34
Although w can be < 0, there seems to be no further impact on the stopping
boundaries in the scenarios we presented above. For a given alpha spending function,
the right-hand side of equation (1.6) is ﬁxed, and the left-hand side is the tail probability
of the multivariate normal distribution function, which is an ellipsoid scaled by the
eigenvalues of the covariance matrix and rotated by the eigenvectors of the covariance
matrix. Solving equation (1.6) sequentially involves ﬁnding the smallest critical values
in a sequential order such that the tail probability is no larger than the value deﬁned on
the right hand side of the equation. For a ﬁxed set of critical values in the region that we
are interested in, the tail probability increases as w decreases, with negligible increases
beyond w = 0. Thus, solving equation (1.6) will result in smaller critical values (smaller
penalty) when w is larger. Recall that w is the correlation coeﬃcient of two eﬃcient
scores ∂l
∂θ1
and ∂2
∂θ2
, and the sign of w is determined by the oﬀ-diagonal element of the
expected Fisher information matrix, which is determined by the covariance of βˆ1 and
βˆ2, where are the unbiased estimators of β1 and β2. When w < 0, the covariance of βˆ1
and βˆ2 is positive.
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4.3 Application to a Bivariate Survival Model
In this section, we show an application for a bivariate survival model where we are
interested in testing whether PFS or the ﬁrst recurrence time is associated with treat-
ment (H0 : β1 = 0) in an earlier interim analysis, but change to testing whether overall
survival or second recurrence time is associated with treatment (H0 : β2 = 0) in a later
interim, or ﬁnal analysis. Alternatively, one may want to focus on mortality or cause
speciﬁc mortality during the interim analysis, and PFS or total mortality at the end
of the trial. Assume that the event time for the ith subject and the jth event type
(i = 1, . . . , N, j = 1, 2) is drawn from a Weibull distribution with shape parameter γ
and frailty ωi. Thus the hazard function of event time of the ith subject and the jth
event type, Tij, is
λij(tij) = ωiγt
γ−1
ij exp(β0 + βjxij),
where xij denotes the explanatory variable for subject i and the jth event type. β0
and βj are the intercept and the coeﬃcient of the explanatory variable respectively.
We consider a model with gamma frailty ωi, and thus f(ωi) =
θθ
Γ(θ)
ωθ−1i exp(−θωi), with
mean 1 and variance 1
θ
. Conditional on ωi, the survival times are assumed independent.
Thus the observed data likelihood is
L(θ, β) =
n∏
i=1
∫ ∞
0
2∏
j=1
[
ωiγt
γ−1
ij exp(β0 + βjxij)exp(−ωitγijexp(β0 + βjxij))
]νij
×
[
exp(−ωitγijexp(β0 + βjxij))
]1−νij θθ
Γ(θ)
ωθ−1i exp(−θωi)dωi, (4.2)
where νij is the censoring indicator (equals 0 for censoring, 1 otherwise), and tij denotes
the event time for subject i and the jth event type. After ωi is integrated out in (4.2),
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the observed data likelihood is given by
L(θ, β) =
n∏
i=1
Γ(θ + Di)
Γ(θ)
(
θ
θ + tγi .(β)
)θ(
γ
θ + tγi .(β)
)Di
× exp
( 2∑
j=1
νij(β0 + βjxij)
) 2∏
j=1
t
(γ−1)νij
ij , (4.3)
where Di =
∑2
j=1 νij and t
γ
i .(β) =
∑2
j=1 t
γ
ijexp(β0 + βjxij).
For ease of exposition, let treatment be the only explanatory variable and therefore
xi = xi1 = xi2 in this particular setting. In most conﬁrmatory clinical trials, there are
only two treatment arms. Based on the likelihood function (4.3) and using the reference
cell coding for convenience (xi = {0, 1}),
w =
I12(β01, β02)√
I11(β01)I22(β02)
=
−E
(
∂2l(β)
∂β1∂β2
)
√(
−E(∂2l(β)
∂β21
)
)(
−E(∂2l(β)
∂β22
)
) |β1=0,β2=0
=
−E[b(t1)b(t2)]√
E
[
(b(t1)− b2(t1))
]
E
[
(b(t2)− b2(t2))
] ,
where l(β) = lnL(θ, β) and b(tk) =
tγkexp(β0)
θ+
P2
j=1 t
γ
j exp(β0)
. E
[
b(t1)b(t2)
]
, and E
[
(b(t1) −
b2(t1))
]
can be solved numerically, since the joint density of the survival times, (t1, t2),
is given by
f(t1, t2) =
Γ(θ + 2)
Γ(θ)
θθexp(
∑2
j=1 β0 + βjxi)γ
2tγ−11 t
γ−1
2[
θ +
∑2
j=1(t
γ
j e
β0+βjxi)
]θ+2 .
However, regardless of the choice of θ, γ, or β0, the value of w will be negative,
meaning that the covariance between βˆ1 and βˆ2 (the oﬀ diagonal elements of the in-
verse expected Fisher information matrix) is positive. As discussed in Section 4.2, the
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boundaries will be the same as the boundaries for the case when w = 0. Further
calculation of w will not be necessary.
4.4 Application to Joint Modeling of Longitudinal
and Time-to-Event Data
Most time-to-event studies also collect repeated measurements of potential biomarkers.
A powerful method to take into account the dependency of time-to-event data and re-
peated measurements of biomarkers is joint modeling of these two data types (Wulfsohn
& Tsiatis 1997, Henderson et al. 2000, Tsiatis & Davidian 2004). Application of joint
models in studying surrogate endpoints was particularly discussed in Taylor and Wang
(2002). It has been demonstrated through simulation studies that use of joint modeling
leads to correction of biases and improvement of eﬃciency (Hsieh et al. 2006, also refer
to results in Chapter 2). Since joint models contain multiple parameters that may be
related to the treatment eﬀect in a joint likelihood, this modeling situation presents an
unique opportunity and advantage of testing diﬀerent parameters at diﬀerent interim
analyses.
4.4.1 Motivation for Testing Diﬀerent Parameters at Diﬀerent
Interim Analysis in Joint Models
In this section, we consider a joint model described in Section 2.2. Based on the hazard
function (2.1) and the trajectory model (2.2), we can see that the overall treatment
eﬀect is βγ+ξ, where γ is the treatment eﬀect on the longitudinal marker, ξ is the direct
treatment eﬀect on time-to-event, and β is the association between the longitudinal
marker and time-to-event. β can also be viewed as measuring the degree of “surrogacy”
between the longitudinal marker and time-to-event. It was suggested by Taylor and
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Wang (2002) that the quantity βγ
βγ+ξ
represents
treatment eﬀect on survival through marker
overall treatment eﬀect on survival
,
which is a measure of surrogacy suggested by Freedman et al. (1992). If Yij is a good
surrogate, the values of β and γ will be relatively large compared to the value of ξ.
In the case of a real surrogate, directly testing the treatment eﬀect may require sub-
stantially more subjects and take longer to observe enough events. A natural question
is whether we can test β and γ jointly. If β 	= 0 and γ 	= 0, then βγ 	= 0. And if βγ and
ξ have the same sign, which is typically the case, the overall treatment eﬀect βγ+ξ 	= 0.
Simulations were carried out to examine the power of testing β, γ and βγ + ξ from
the joint model (2.3). In this simulation study, the event time was simulated from an
exponential model with λi(t) = λ0 exp{βXi(t) + ξZi}, where Xi(t) = θ0i + θ1it + γZi
and λ0 = 0.85. To ensure a minimum follow-up time of 0.75 years (9 months) and max-
imum follow-up time of 2 years, right censoring was generated from a uniform [0.75, 2]
distribution. The (θ0i θ1i) were assumed to follow a bivariate normal distribution with
μθ =
⎛
⎜⎝ 0
3
⎞
⎟⎠ and Σθ =
⎛
⎜⎝ 1.2 0
0 0.7
⎞
⎟⎠. We simulated 1000 datasets and each dataset
had 200 subjects (100 subjects per treatment group). Power was determined as the %
of datasets with a p-value from the score test ≤ 0.05 for testing
⎧⎪⎨
⎪⎩
H0 : β = 0 or γ = 0
H1 : β 	= 0 and γ 	= 0
(4.4)
versus
⎧⎪⎨
⎪⎩
H0 : βγ + ξ = 0
H1 : βγ + ξ 	= 0
. (4.5)
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TABLE 4.4: Comparison of Power for Testing {β = 0 or γ = 0}, and βγ+ ξ = 0 from
the Joint Model
H0 : β = 0 or γ = 0 H0 : βγ + ξ = 0
β γ ξ β Estimate (SE) γ Estimate (SE) Power Estimate (SE) Power
0.2 0.25 0.05 0.210 (0.056) 0.250 (0.130) 46.6% 0.095 (0.170) 9.7%
0.2 0.15 0.15 0.210 (0.056) 0.149 (0.130) 25.6% 0.176 (0.168) 18.8%
Rejecting H0 in (4.4) implies rejecting H0 in (4.5) unless the direct treatment eﬀect
on time-to-event ξ has a complete opposite eﬀect compared to βγ. Table 4.4 shows
substantial power advantages for testing β and γ jointly instead of testing βγ+ξ alone,
especially when the size of ξ is relatively small.
4.4.2 Stopping Boundaries in a Hypothetical Design
Let ϕ = βγ + ξ. The likelihood function (2.3) can be reparameterized in terms of β, γ
and ϕ by replacing ξ with ϕ−βγ. Let Zβ(l), Zγ(l), Zϕ(k) denote the score test statistics
of β and γ at the lth analysis, and of ϕ at the kth analysis. Then based on equation
(4.1) of Section 4.2, Cov
(
Zβ(l), Zϕ(k)
)
=
√
nl
nk
I(β0,ϕ0)√
I(β0)I(ϕ0)
, and Cov
(
Zγ(l), Zϕ(k)
)
=√
nl
nk
I(γ0,ϕ0)√
I(γ0)I(ϕ0)
, where I(β0), I(γ0) and I(ϕ0) are the diagonal elements of the expected
Fisher information matrix and I(β0, ϕ0) and I(γ0, ϕ0) are the oﬀ-diagonal elements of
the expected Fisher information matrix.
Suppose that in a study with two planned analyses, we are interested in testing Hy-
pothesis (4.4) in the interim analysis, and testing Hypothesis (4.5) in the ﬁnal analysis.
To ensure the type I error will not exceed the planned level of 0.05 in two-sided tests,
the boundary values zc(1) and zc(2) can be determined successively so that
P0
{
|Zβ(1)| ≥ zc1(1) ∪ |Zϕ(2)| ≥ zc1(2)
}
= αβ(t
∗
k) (4.6)
P0
{
|Zγ(1)| ≥ zc2(1) ∪ |Zϕ(2)| ≥ zc2(2)
}
= αγ(t
∗
k). (4.7)
Note that both (4.6) and (4.7) need to be satisﬁed as the parameter space under
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H0 for the ﬁrst interim analysis is the set {β : β = 0} ∪ {γ : γ = 0}. The two sets in
the null hypothesis parameter space can be completely disjoint.
The likelihood function of (2.3) does not have a closed form, thus a direct estimate
of the expected Fisher information matrix will be diﬃcult. One possible solution is
to approximate the likelihood function by a Laplace approximation and obtain the
approximate expected Fisher information matrix. However, this can also be a daunting
task, and the estimates may not be accurate as it will also depend on the assumptions
regarding other nuisance parameters, such as σ2e . Based on our simulated data, we
obtained negative
I(n)(β0,ϕ0)√
I(n)(β0)I(n)(ϕ0)
and
I(n)(γ0,ϕ0)√
I(n)(γ0)I(n)(ϕ0)
values, where I(n) stands for the
observed information. This is expected since the correlation between ϕ and β (or γ)
is usually positive, resulting in w < 0. Therefore it is fairly safe to derive a set of
boundaries by assuming w = 0 between β (or γ) and ϕ.
It is possible that a diﬀerent alpha spending function can be used in (4.6) and
(4.7), and therefore result in diﬀerent crossing boundaries for β and γ. However the
second stopping boundary should take the maximum of zc1(2) and zc2(2). In the joint
modeling setting, as additional longitudinal data may be collected for subjects who
are included in the previous interim analysis, information accumulated between each
interim analysis is not independent. The covariance between the test statistics has an
extra term b =
E(SlS∗k−l)√
IlI
∗
k
(refer to (4.1) in Section 4.2). As suggested by DeMets and Lan
(1994), the information fraction between successive test statistics will be more complex
and will not be exactly known. In this design, we argue that w < 0 implies negative
E( ∂l
∂β
, ∂l
∂ϕ
) and negative E( ∂l
∂γ
, ∂l
∂ϕ
). Therefore, the impact on the stopping boundaries
may be negligible.
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4.5 Discussion
In this paper, we have extended the concept of the alpha spending function to testing
diﬀerent parameters at diﬀerent interim analyses. Correlations between successive test
statistics not only depend on the number of accumulated subjects between interim anal-
yses, but they also depend on the expected Fisher information matrix. The correlation
between the two parameter estimates is inversely related to the oﬀ diagonal elements of
the expected Fisher information matrix. Thus, when w is positive, the two parameters
have negative association, and the additional penalty to pay to test diﬀerent parame-
ters is smaller. When w is negative, the two parameters are positively associated, and
the additional penalty for testing diﬀerent parameters is larger. The expected Fisher
information matrix should be evaluated under H0. However, assumptions about other
nuisance parameters may be required. In cases with complex likelihood functions, the
expected Fisher information matrix can be diﬃcult to obtain. We suggest that future
stopping boundaries can be calibrated using the observed information matrix obtained
in interim analyses prior to changing the parameters. Although expression (4.1) is
derived based on the score test, the same boundaries can be applied to diﬀerent test
statistics as the test statistics will have a similar covariance structure.
As discussed by Fleming and DeMets (1993), early termination of a clinical trial is
a complex process and cannot be simply reached by pre-speciﬁed stopping rules. For
example, even when the eﬃcacy stopping boundary is crossed, a trial may need to be
continued to collect suﬃcient safety information. We simply provide a tool here to
facilitate the decision process and ensure that the type I error will be strictly under
control to its pre-speciﬁed level when testing diﬀerent parameters at diﬀerent interim
analyses. Furthermore, we are not advocating that when a particular hypothesis is not
performing well in terms of signiﬁcance at a particular interim analysis, we test another
hypothesis at subsequent interim analyses. The hypothesis tests should be pre-speciﬁed
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before the trial begins, and the analysis should be based on the joint likelihood in all
interim and ﬁnal analyses. If the analyses are based on diﬀerent likelihood functions,
or the value of w cannot be reliably estimated, w should be set to 0, assuming no
correlation between the test statistics. This will result in the most conservative stopping
boundaries.
The application to joint modeling of longitudinal and time-to-event data is promis-
ing in the case that the longitudinal marker is a good surrogate for the time-to-event.
In reality, time-to-event data, such as overall survival, may be lengthy to obtain. Re-
searchers have been trying to ﬁnd important predictors or surrogates which are strongly
associated with time-to-event which can be collected in a shorter period of time. With
recent advances in genetic research and other biomarker research, many potential sur-
rogates are being identiﬁed. For example, Circulating tumor cells (CTC’s) have been
found to be associated with progression-free survival and overall survival in patients
with metastatic breast cancer (Dawood et al. 2008, Liu et al. 2009). If both β 	= 0 and
γ 	= 0, it may be considered suﬃcient eﬃcacy evidence to terminate the trial early. If
the longitudinal marker is a weak surrogate, this will allow the investigator to proceed
to the next analysis to test the hypothesis that βγ + ξ 	= 0.
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